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IMIDAZOLE-BASED PH-SENSITIVE CONVERTIBLE LIPOSOMES
FOR ANTICANCER DRUG DELIVERY
Abstract
By Ruiqi Huang
University of the Pacific
2020
Solid tumors possess biological features that are different from those in healthy tissues,
which provides opportunities of anticancer treatment by nanomedicines. Due to the presence of
the fenestrated tumor vasculatures, nanomedicines can selectively accumulate in tumor tissues by
the enhanced permeability and retention (EPR) effect. The acidic pH in tumor interstitium (pH
6.0-7.0) also provides a promising mechanism to trigger the nanomedicines to promote the
cellular uptake of cargo drugs. The previously reported stealth liposomes coated with PEG are
known to accumulate in tumors owing to their prolonged circulation time. The PEG coating on
liposomes can hinder serum protein adsorption and thus prevent rapid elimination by the
reticuloendothelial system, thus increasing the liposome circulation time. However, liposomal
interaction with cancer cells can also be hindered by the PEG coating.
In order to improve the anticancer activity of stealth liposomes, novel synthetic
imidazole-based lipids were introduced to the composition of stealth liposomes to develop the
pH-sensitive imidazole-based convertible liposomes (ICL). At acidic pH, the imidazole-based
lipids would protonate to acquire positive charges, thus clustering with the negatively charged
PEGylated lipids. Such lipid-lipid electrostatic interaction would induce phase separation of the
bilayer to generate a PEG-free domain that displays excess positive charges. Such newly
converted, cationic liposomes at acidic pH in tumor interstitium would have better interaction

8

with negatively charged cancer cells and/or enhanced drug release, therefore overcoming the
drawback of traditional stealth liposomes.
After synthesizing the imidazole-based lipids DHI, DHMI and DHDMI, we constructed
doxorubicin (DOX)-loaded ICL formulations. The physicochemical properties of ICL were
characterized, and factors influencing such properties were explored. The pH-triggered
acquisition of positive charges of ICL was confirmed by the elevation of ζ- potentials and
aggregation with negatively charged model liposomes that mimic bio-membranes at acidic pH
6.0-7.0. Acidic pH-triggered release of ICL was confirmed by drug release assays. It was also
found that although the incorporation of cholesterol can remarkably reduce the size and increase
the encapsulation efficiency (EE) of ICL, it also hinders the pH-sensitivity of ICL. The
morphology of ICL at both pH 7.4 and pH 6.0 was characterized under transmission electron
microscopy (TEM), which showed morphological changes in response to acidic pH 6.0, which
further supported the proposed pH-sensitivity of ICL.
Cytotoxicity assays on 3D MCS of HeLa, A549, MDA-MB-231 and MDA-MB-468 cell
lines were conducted to evaluate the anticancer activity of ICL formulations. ICL formulations
without cholesterol showed considerably enhanced anticancer activities against MCS compared
with the non-sensitive stealth liposomes (NSL). However, incorporation of cholesterol decreased
such activities. The IC50 values of cholesterol-free ICL and ICL with cholesterol against MCS
strongly suggested that the pH-sensitivity introduced by the imidazole-based lipids would
enhance the anticancer activity of stealth liposomes, while the hindrance of the pH-sensitivity by
cholesterol would reduce such activities.
Taken together, ICL’s pH-sensitivity is correlated with their enhanced anticancer activity
than non-sensitive stealth liposomes.
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CHAPTER 1: INTRODUCTION

1.1 Cancer and Solid Tumor
1.1.1 Introduction on cancer. Cancer is a generic term of a group of diseases that
involves abnormal growth, migration, and invasion of cells [1]. Mostly, cancer is known as
malignant tumors with the potential to invade to other parts of the body, which are in contrast to
benign tumors that do not spread. Cancer is the second leading cause of death globally, and over
100 types of cancers have been found [2]. Five to ten percent of cancers are caused by genetic
hereditary while vast majority of cancer are induced by external factors including tobacco use,
obesity, lack of physical activity, excessive drinking of alcohol, and infections such as
Helicobacter pylori, hepatitis and HIV [3]. Cancers show symptoms such as lumps, abnormal
bleeding, weight loss, and can be diagnosed by screening tests, medical imaging, and biopsy [4].
Cancer is typically treated with combination of radiation therapy, chemotherapy, targeted therapy
and surgery.
1.1.2 Biological features of solid tumors. Neoplasm, also named solid tumors, is a type
of abnormal and excessive growth of tissue in body, which can be classified into benign tumors,
potential malignant tumors and malignant tumors. Malignant tumors will be the only type of
solid tumors for discussion in this thesis.
The physiology of solid tumors differs from that of normal tissues in a variety of aspects.
Most of the biological features of solid tumors originate from the difference of vasculatures
between normal and tumor tissues [5]. In contrast to the healthy, orderly vasculature of normal
tissues, tumor blood vessels have more distended shape, more leaky walls and more sluggish
blood flow. Due to the rapid growth of cancer cells, new blood vessels are grown in tumors in
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order to maintain the basic supply of oxygen and nutrients. However, those blood vessels are
usually poorly formed, which leads to several biological features in solid tumors, including
hypoxia, necrosis, acidic microenvironment, unique extracellular matrix (ECM), and drug
resistance.
1.1.2.1 Hypoxia in solid tumors. The metabolic hypoxia in solid tumors is a
pathophysiological consequence of the disturbed vasculature and the deterioration of diffusion
conditions [6]. When a tumor’s oxygen supply is not restricted, its oxygen consumption rate and
adenosine triphosphate (ATP) production is comparable with those in normal tissues. However,
as the tumor grows larger, regions that lack microcirculation cannot obtain adequate supply of
oxygen from blood vessels. Such regions enter a condition of hypoxia, which features
progressive decrease of oxygen partial pressure and cellular ATP production. Hypoxia in tumors
is largely associated with tumor propagation, malignant progression and resistance to therapy.
Therefore, hypoxia has become a major issue in cancer treatment [6]. Hypoxia induces proteome
changes in cancer cells and stromal cells in tumors, which in turn causes cellular quiescence,
differentiation, apoptosis, and necrosis [7]. Evidence is accumulating that hypoxia in solid
tumors drives malignant progression of cancer cells, which is marked by increasing probability
of metastasis and increasing resistance against nonsurgical therapy (e.g. radiotherapy and
chemotherapy) concomitant with tumor growth [8, 9].
1.1.2.2 Necrosis in solid tumors. Necrosis occurs in most solid tumors. The edges of
necrotic regions in tumors were found to be parallel to the neighboring blood vessels, suggesting
that the necrosis is caused by limited diffusion of adequate oxygen and nutrients into cancer cells
as well as limited transfer of metabolites from cancer cells to the blood vessels [10]. A relatively
constant distance between blood vessels and the edge of necrotic regions, typically 100 to 200

23

μm, was observed in tumors, which is consistent with the estimated distance of sufficient oxygen
diffusion in tissues [11]. Such in-between areas contain cells that are still viable but with very
low level of oxygen. This type of quiescent cells, together with the necrotic cells farther away
from the blood vessels and the proliferative cells closer to the blood vessels, constitute the highly
heterogeneous tumor tissues.
1.1.2.3 pH gradients in solid tumors. Acidic pH is a major feature of tumor tissues and
is typically represented by two pH gradients in solid tumors: the reversed gradient between pHi
and pHe, and the pH gradient between the outer and center region of tumors. Normal cells in
healthy tissues have an intracellular pH (pHi) of 7.2 and a slightly higher extracellular pH (pHe)
of 7.4. In contrast, cancer cells in tumor tissues are characterized by a relatively higher pHi of
7.2 and a lower pHe of 6.0-7.0 [12]. This “reversed” pH gradient in tumors not only provides
essential support for the growth, invasion and migration of tumors, but also helps protect the
tumors from anti-tumor immunity and apoptosis [13]. The pHe of cancer cells also varies in
different regions of solid tumors. The pH in the outer proliferative and quiescent areas average
around pH 7.0, while the pH in the tumor cores generally drops to 6.1-6.4[14, 15].
The acidic pH in solid tumors results from the accumulation of the metabolic by-product
of hypoxia – lactate. Under the condition of low oxygen and nutrient concentrations, cancer
cells tend to produce lactate from the anaerobic glycolytic pathway more than oxidative
phosphorylation for energy production [16]. In consequence, lactate accumulates in the tumor
interstitium, especially in the tumor core where the oxygen penetration and waste removal are
extremely restricted. The accumulation of the acidic lactate contributes to decrease of pH in
tumor interstitium, leading to drug resistance [17]. Therefore, it has been considered a potential
therapeutic strategy to inhibit the production and transport of lactate [18].
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1.1.2.4 Extracellular matrix (ECM) in solid tumors. Extracellular matrix (ECM), a
highly dynamic structure, is the major structural component in tumor microenvironment. The
ECM of cancer cells provides both biochemical and physical support for the solid tumor, and is
distinct in its composition and stiffness compared with normal ECM [19]. The dynamics of
ECM in solid tumors becomes abnormal due to the disruption of equilibrium between the
synthesis and secretion of ECM components and the expression of matrix-remodeling enzymes.
The ECM in tumors contains a variety of proteins, including fibrous protein, glycoproteins,
proteoglycans, and polysaccharides. The fibrous ECM proteins, such as collagen, partake in
tumor tissue development by providing mechanical strength, altering cell adhesion, and
promoting cell migration [20]. Glycoproteins in tumors make the ECM a cohesive network to
link cells together with structural components, such as fibulin, fibrillin, and laminin.
Proteoglycans play a crucial role in ECM assembly and cell signaling by binding with growth
factors and acting as co-receptors of ligands. Polysaccharides, such as hyaluronic acid (HA),
play a role in filling the interstitial space and buffering physical stress on the ECM. In addition
to the biochemical effects, the tumor ECM also provides a physical barrier that hinders the
transport of water, solutes and chemotherapeutics [21]. Due to the overexpression of many ECM
components, tumor ECM is typically stiffer than ECM in healthy tissues.
1.1.2.5 Opportunities provided by biological features of solid tumors. Conversely, the
aforementioned biological features of solid tumors, such as deformed vasculature, hypoxia and
physical barriers from ECM also provide opportunities of anticancer treatment. For example,
Tirapazamine (TPZ), can be activated by the hypoxia to selectively kill cancer cells in solid
tumors [5]. Nanomedicines can diffuse across the more porous tumoral blood vessels to
selectively accumulate in solid tumors [22]. The acidic pH in tumor interstitium can enhance
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drug release from pH-sensitive drug delivery systems [23]. Some gene therapeutics have been
developed to be activated by hypoxia or necrosis of solid tumors [24, 25].
1.2 Anticancer Drugs
1.2.1 Introduction on anticancer drugs. Generally, anticancer drugs are classified
according to their mechanism of action. Major groups of anticancer drugs include cytotoxic
drugs, hormonal drugs and targeted drugs. Correspondingly, three major modalities are included
in cancer pharmacotherapy. The cytotoxic chemotherapy connotes the use of non-specific
cytotoxic drugs to suppress cancer cell mitosis and division, but excludes therapeutic agents that
are more targeted or block extracellular signals [26]. Therapies that inhibit tumor growth signals
from endocrine hormones are called hormonal therapies, which are specifically applied in
treatments of breast cancer and prostate cancer [27]. Therapies that inhibit tumor growth signals
associated with specific targeted receptors are referred as targeted therapies [28]. Because
anticancer drugs are administrated into the blood circulation, they represent a type of systemic
therapy and could address cancer at any location in the body. Such systemic anticancer therapy
is usually in conjunction with local anticancer therapy, such as radiation therapy, surgery, and
hyperthermia therapy, which exert anticancer effects only where they are applied [29].
1.2.2 Challenges and limitations of cytotoxic chemotherapies. Chemotherapy, usually
referred as chemo or CTX, is a type of cancer treatment that uses single or multiple cytotoxic
drugs. Closely correlated to medical oncology, chemotherapy is one of the major categories of
pharmacotherapy for cancers [30]. Conventional chemotherapeutic agents inflict toxicity to cells
and interfere with their mitosis. The cytotoxic drugs in conventional chemotherapy are classified
to antimetabolites (e.g. Methotrexate and Gemcitabine), alkylating agents (e.g. Cisplatin and
Carboplatin), microtubule damaging agents (e.g. Vincristine and Vinblastine), topoisomerase
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inhibitors (e.g. Etoposide and Topotecan), antibiotics (e.g. Doxorubicin and Bleomycin) and
other miscellaneous agents (e.g. Tretinoin and Hydroxyurea). In general, chemotherapy using a
combination of cytotoxic drugs have shown better efficacy than a single cytotoxic drug [31].
Poor selectivity is the major drawback of chemotherapy. Because cancer cells originate
from normal cells, anticancer drugs that inhibit the growth of cancer cells are also cytotoxic to
normal cells. Many of the side effects of chemotherapy are attributed to the damage of normal
cells that are sensitive to anti-mitotic drugs, including those in digestive tract, bone marrow and
hair follicles [32]. Therefore, common side effects of chemotherapy include decreased
production of blood cells, mucositis in gastrointestinal tract and hair loss. For example,
cyclophosphamide and methotrexate, which are commonly used agents for breast cancer are
known to cause neutropenia, alopecia and emesis [33]. Moreover, cisplatin is widely known to
have nephrotoxicity due to accumulation of transported cisplatin in the kidney [34], and
doxorubicin has been known to have cardiotoxicity, which may induce arrhythmias, pericarditis,
myocarditis and acute heart failure [35].
Besides poor selectivity, chemotherapy is also limited by drug resistance, which is a
major cause of failure of chemotherapeutic drugs. One cause of drug resistance is that cancer
cells overexpress transporters that that protect them from chemotherapeutics [36]. The
transporters (e.g. p-glycoprotein) can be overexpressed on cancer cell surface to move drugs
from cytosol to the interstitium. Agents that inhibit the transporters have been developed, but not
yet approved for clinical use due to toxicity [37]. Another cause of drug resistance is gene
amplification that induces multiple copies of a cancer cell, which is against the effect of
chemotherapeutics on the gene expression in cell proliferation [36]. Furthermore, the cellular
pathways of apoptosis can be defective in cancer cells, which increased cancer cell survival
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when exposed to chemotherapeutics. Additionally, the DNA damage exerted by chemotherapy
agents can be repaired by enzymes in some cancer cells [38]. Besides resistance against a single
drug, cancer cells may also develop resistance against a group of drugs with similar mechanism
and cross-resistance against several drugs of different targets and mechanisms [39].
Chemotherapy is also facing challenges in effective drug distribution and penetration due to the
deformed vessels in tumors. New blood vessels are formed in tumors as they grow larger, but
such tumoral blood vessels have poor structure and are only distributed in the peripheral region
of a solid tumor. Therefore, the core of a solid tumor usually has inadequate blood supply, and
consequently poor drug distribution[40].
1.2.3 Targeted anticancer drug delivery. Targeted drug delivery, also known as smart
drug delivery, is a method that delivers drug(s) to a patient at higher concentration at the
targeted site of action [41]. Targeted drug delivery systems aim to have prolonged and localized
drug interaction with the diseased tissue to improve the efficacy. Moreover, targeted drug
delivery aims to decrease the side effects of cytotoxic chemotherapy by decreasing the
concentration of the cytotoxic anticancer drug in healthy tissues [42]. Targeted drug delivery
systems have strong market prospects, because the reduced toxicity means significantly
improved survival and life quality for cancer patients. The drawback of targeted delivery
systems is the higher cost that makes production and dosage modification more challenging.
Targeted drug delivery has been closely associated with the development of nanomedicines.
Generally, the strategies of drug targeting in such drug delivery systems can be classified into
passive targeting and active targeting [42, 43].
1.2.3.1 Passive targeting. Passive targeting, also known as physical targeting, increases
drug accumulation in diseased tissues by taking advantage of the physical characteristics of the
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delivery system [45]. The passive targeting for cancer treatment is directly related to the
circulatory system and is assisted by the enhanced permeation and retention (EPR) effect.
Translocation of molecules through vascular interspace is closely dependent on the sizes of
molecules and the vasculature morphology. The short half-life of conventional
chemotherapeutics in blood circulation and their indiscriminate accumulation in healthy tissues
are attributed to their small size (generally < 1000 Da), which lead to extravasation through
vascular pores in healthy tissues (50-150 nm) [44]. This mode of biodistribution constitutes poor
selectivity and thus high general toxicity of conventional, small molecule chemotherapy agents.
In comparison, blood vessels in tumors carry pores in the size range of 200-1200 nm [45],
resulting in enhanced vascular permeability and lowered clearance of nanomedicines in the size
range of 100-200 nm. Therefore, the fenestrated neovascular wall in tumors elicits selective
accumulation of nanomedicines but not small molecular drugs (Figure 1.1). However, extended
half-life of a nano drug delivery system in blood circulation is necessary for its passive targeting
into tumors. In order to achieve the prolonged circulation in blood, a nano drug delivery system
is often coated with hydrophilic polymers, such as polyethylene glycol (PEG) to hinder its
recognition and elimination by the reticuloendothelial system (RES) [46].

Distribution Phase

Low MW Drugs

Nanomedicines
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Elimination Phase

(Figure 1.1 Continued)

Figure 1.1. Conventional low molecular weight (MW) drugs versus nanomedicines: low MW
drugs showed high accumulation in both healthy tissues (upper to the vessel, pink) and tumor
tissues (lower to the vessel, dark red), while nanomedicines showed specific promoted
accumulation in tumor tissues. [47]
Passive targeting provides great advantage in nanomedicine therapy but it also faces
several challenges. One challenge for the EPR effect is the vascular features in tumors. The
vascular density varies in different types of cancers. Specifically, it was found hepatic and renal
carcinoma had stronger EPR effect than pancreatic and prostate cancers [47]. Moreover, the
vessel distribution within a tumor is heterogeneous. It was reported that drug distribution is
limited in the central necrotic regions in tumors, which are far from the blood vessels and
therefore little impacted by EPR effect, which relies on vascular permeability [48]. Another
challenge for the EPR effect is the stromal compartment in tumors, which is composed of ECM
and stromal cells. The ECM components, such as collagen and hyaluronic, form a dense barrier
against the penetration of nanomedicines from blood vessels to tumor interstitium [49]. Several
studies have confirmed that nanomedicine accumulation is compromised in collagen-rich tumors,
as the composition and distribution of collagen in tumors causes heterogenous distribution of
drug delivery systems [50].
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1.2.3.2 Active targeting. Active targeting takes effect based on the phenotypic and
biochemical characteristics in diseased tissues. In addition to passive targeting, active targeting
would help drug delivery systems take effect more specifically at targeted sites and spare healthy
tissues [51]. Active targeting can be accomplished using several approaches, which are divided
into ligand-receptor binding, activated targeting, and locally activated targeting.
The most common active targeting strategy is ligand-receptor binding, which employs
biological interactions between ligand and its receptor [52]. Drug delivery systems containing
specific ligands would selectively bind with their coupling receptors, which are overexpressed on
the surface of tumor cells but not normal cells, in order to localize the payload drug to tumor
tissues [53]. It was reported the ligand-receptor binding may trigger endocytosis and cellular
drug uptake, which helps suppress the multidrug resistance of tumor [54]. For example,
transferrin has been utilized to mediate endocytosis by conjugating with nano-formulations and
then interacting with receptors on cell membranes. The transferrin-conjugated nanoformulations showed better cellular uptake than the non-conjugated counterparts [54]. One of
the major challenges for the ligand-receptor mediated active targeting is the limited selectivity.
Firstly, selectivity of such active targeting is compromised by the heterogeneity of receptor
expression by cancer cells. Different receptors are expressed in various types of cancers;
receptors are expressed differently in the same tumor at different developmental stages; cultured
cancer cells in vitro may not express the same receptors as in vivo tumor cells – all these means
that heterogeneity leads to imprecise evaluation of drug delivery systems [55]. Secondly,
selectivity also relies on receptor density on cancer cells. Such active targeting would only take
effect where the receptor is considerably over expressed by cancer cells than normal cells [55].
The third challenge for active targeting is the limited binding. The binding is associated with
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both the distance and the affinity between a ligand and its receptor. The binding would occur
only when the distance between the ligand and the receptor is smaller than 0.5 nm, beyond which
the delivery system would not accumulate at the targeted site [56]. Moreover, excessive binding
between the ligand and the receptor may generate a binding-site barrier, which would hinder the
uptake of therapy agents by tumors [32].
One strategy to achieve active targeting is called locally activated drug delivery, which
initiate the formulation-cell interaction and the drug release by signals that are specific to the
diseased site such as pH, or by external stimuli such as temperature, ultrasound, light and
magnetic field [57, 58]. This type of delivery systems is also known as stimulus-sensitive
systems. Some locally active drug delivery systems are sensitive to specific signals generated by
the abnormal biochemical properties of tumors, such as the acidic microenvironment and the
lower redox potential due to hypoxia [59, 60]. Some locally active drug delivery systems can
achieve enhanced release in response to external stimuli, such as ultrasound, light, magnetic field
and electric field [61-64].
1.2.4 Anticancer nanomedicines. Nanomedicine, also named nanotherapeutic, is
defined as the application of nanomaterials and nanotechnology for medical purposes [65].
Nanomedicine represents an emergent field address issues of conventional anticancer drugs.
Designs of nano-drug delivery systems aim to maximize bioavailability both at specific sites and
over a desirable period of time. Loading therapeutic agents into lipid- or polymer-based
nanoparticles can help improve the pharmacokinetics of therapeutics, such as reduced
distribution volume, lowered clearance rate and longer circulation time [65]. Targeted
nanomedicines have lowered overall drug consumption and decreased toxicity by accumulating
and releasing drugs selectively in the diseased regions at no higher dose than needed [66].
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Nanomedicines have also been applied to improve anticancer immunotherapy by delivering
specific tumor microenvironment (TME)-normalizing agents [67]. Nano-formulations can also
deliver multiple drugs to counterdrug resistance and to achieve synergistic therapeutic effects
[68]. Application of amphiphilic materials such as phospholipids in nano-formulations, helped
enhance the solubility, stability and bioavailability of lipophilic drugs in blood circulation [69].
Furthermore, the 10-200 nm size range of nanomedicines significantly benefits their drug
delivery. Compared with small molecule therapeutics, the larger surface area of nanomedicines
improve their interaction with biological membranes [70]; compared with larger delivery systems
such as microspheres and microcapsules, nanomedicines are less invasive and have shorter
biochemical reaction time [71].
Nanomedicines are classified into lipid nanosystems, polymeric NPs, engineered NPs,
dendrimers, nanotubes, fullerenes, quantum dots, and viral vectors. Among them, lipid
nanosystems include liposomes, solid lipid nanoparticles (SLNs), lipid-based micelles, emulsions
and lectin-modified SLNs [72]. Ideal nanocarriers of therapy agents are expected to possess high
bio-capacity, low toxicity and low immunogenicity. However, the toxicity of nanocarriers
themselves, namely nanotoxicity, has recently become a concern for their medical applications
[73, 74]. Investigations on limitations of nanomaterials are still ongoing in order to broaden their
applications in health sciences.
1.2.5 Doxorubicin (DOX) and DOX-loaded Nano-formulations. Doxorubicin (DOX
or DXR) (Figure 1.2), with the brand name Adriamycin, was approved in U.S. in 1974. DOX is
administrated by intravenous (IV) injection to treat a wide range of cancers, including breast
cancer, ovarian cancer, bladder cancer, lymphoma, Kaposi’s sarcoma, and acute lymphocytic
leukemia [75]. DOX belongs to anthracyclines, a group of chemotherapy agents extracted from
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Streptomyces bacterium, and is one of the most effective anticancer medications [76]. DOX is a
fluorescent molecule with a maximum excitation wavelength at ~485 nm and emission between
560-590 nm. The broad spectrum of anticancer activity and the fluorescence makes DOX one of
the most commonly used payload drugs in the development of anticancer drug delivery systems.
Cytotoxicity of DOX is based on two different mechanisms. Firstly, DOX intercalates into DNA
to inhibit the function of topoisomerase II (TOP II), which induces DNA breakage and cell death.
Furthermore, DOX is also known to generate free radicals that damage cell membranes, DNA,
and proteins, which is another mechanism to induce cell death [77].

C27H29NO11
Exact Mass: 543.17
Mol. Wt.: 543.52
m/e: 543.17 (100.0%), 544.18 (30.9%), 545.18 (6.8%), 546.18 (1.1%)
C, 59.66; H, 5.38; N, 2.58; O, 32.38

Figure 1.2. Chemical structure of DOX.
Common side effects of DOX include hair loss, nausea and vomiting, diarrhea, missed
menstrual periods, loss of appetite, weakness, tiredness, and reddish color in urine, tears and
sweat [75]. Moreover, DOX is known to cause severer and possibly life-threatening
cardiotoxicity. To mitigate the dose-limiting side effects, DOX-loaded nanomedicines have been
developed, including Doxil®, Myocet™, ThermoDox®, LipoDox®, and Caelix® [78-80].
Doxil, the DOX-encapsulated long-circulating stealth liposomes, was the first nano-sized
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liposomal product to obtain regulatory approval [79]. It was approved in the U.S. in 1995 for the
treatment of ovarian cancer and AIDS-related Kaposi’s sarcoma. The mean diameter of Doxil
liposomes is 80-90 nm and each lipid vesicle can encapsulate up to 15000 DOX molecules [81].
Many studies have demonstrated that, compared with free DOX, Doxil has a drastically lower
cardiotoxicity and substantially higher efficacy, both owing to its preferred accumulation at
tumor sites [82, 83]. Owing to the nanometer size, Doxil can accumulate at tumor sites based on
the mechanisms of passive targeting (1.2.3.1). The PEG coating of Doxil hinders its recognition
by the RES system (1.3.4.2), thereby increasing its circulation time to consolidate the passive
targeting.
1.3 Liposomes
1.3.1 Introduction of liposomes. As one of the nanocarriers, liposome is a type of nanoscaled spherical vesicles which consist of a lipid bilayer shell and an aqueous interior. The
bilayer structure is attributed to the special properties of lipids. Most liposomes are composed of
phospholipids, which are amphiphilic molecules carrying a hydrophilic head consisting of a
phosphate group and a lipophilic tail consisting of two fatty acid chains. When phospholipids
are dispersed in water, they spontaneously form enclosed bilayer structures. The amphiphilicity
of phospholipids makes liposome a versatile carrier for both hydrophilic and hydrophobic drugs.
Composition of liposomes may also include other lipids such as cholesterol, as long as they are
compatible with the lipid bilayer [84]. There are currently more than ten clinically used
liposome-based products and hundreds of new liposome formulations in clinical trials. So far
liposomal formulations of anticancer and antifungal agents have been commercialized [85].
1.3.2 Preparation of liposomes. Liposomes can be prepared by several types of
methods. Thin-film hydration is the most widely used preparation method in research labs in
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which a dry film of lipids is prepared and then hydrated in an aqueous medium [78]. Ethanol
injection method is commonly used in industrial manufacturing of liposomes, in which an
ethanol solution of lipids is rapidly injected into an aqueous medium through a needle to disperse
the lipids and promote the vesicle formation [78]. Other methods include reverse-phase
evaporation and freeze-drying [79]. Techniques such as freeze-anneal-thawing, membrane
extrusion, sonication and homogenization are applied to control the size and size distribution of
liposomes [78].
In preparation of drug-loaded liposomes (Figure 1.3), hydrophobic drugs can be mixed
with the compositional lipids in the thin film to incorporate into the lipid bilayer during film
hydration/ethanol injection, while hydrophilic drugs can be encapsulated either passively by
using an aqueous drug solution for film hydration/ethanol injection or actively by remote loading
with an ion gradient. Many liposome formulations encapsulate DOX by the remote loading
method [81]. Remote loading, also known as active loading, efficiently drives DOX molecules
into the liposomes by a transmembrane ion gradient from a highly concentrated salt solution in
the aqueous interior of liposomes. Traditionally, DOX is loaded by a pH gradient established by
a concentrated ammonium sulfate solution in the aqueous liposome interior (Figure 1.4), which
maintained the pH at pH 4-5. The remote loading occurs when DOX molecules diffuse from the
bulk media to the liposome aqueous interior, where they are protonated at the acidic pH and then
form a sulfate salt precipitate, which enables high drug loading and stable drug retention [85].
This remote loading driven by ammonium sulfate is less effective when the intraliposomal pH is
neutral or slightly basic. As improved alternatives, metal salts such as manganese sulfate and
copper gluconate have been reported to achieve high loading efficiency at pH > 6.5 [86, 87] by
forming DOX-metal complexes inside the liposomes.
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Aqueous buffer

Lipid/drug
ethanol solution
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Ethanol injection
Lipid/drug
organic solution

Lipid/drug
membrane

c.

d.

Drug aqueous buffer

Film formation
Lipid organic
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Aqueous buffer

Lipid ethanol
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Film hydration

Ethanol injection
Drug aqueous buffer
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Figure 1.3. Schematic of preparation methods of drug-loaded liposomes. (a) Hydrophobic drugloaded liposomes with film hydration method. (b) Hydrophobic drug-loaded liposomes with
ethanol injection method. (c) Hydrophilic drug-loaded liposomes with film hydration method. (b)
Hydrophilic drug-loaded liposomes with ethanol injection method. [86]

2DOX-NH3+ + 2Cl-

2DOX-NH2 + 2H+

(NH4)2SO4
2NH4 + SO422NH3
Exit

2NH3 + 2H+
2DOX-NH2 + SO42- + 2H+
(DOX-NH3)4SO4
Precipitate

Figure 1.4. Remote loading of DOX into liposomes by ammonium sulfate gradient. (a) Reactions
occurring inside and outside of the vesicles which caused (DOX-NH3)4SO4 precipitate. (b) Spatial
structure of DOX-NH2 and (DOX-NH3)4SO4.
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1.3.3 Advantages of liposomal drug delivery systems. The liposomal drug delivery
system was first proposed in 1961, and now has shown many applications in delivery of small
molecule drugs, biomolecules and genes [87]. Liposomes are the most commonly utilized
nanocarriers for targeted drug delivery due to a number of advantages [88]. Firstly, liposomes
are able to carry a variety of cargo molecules, including small molecules, proteins, nucleotides
and plasmids [85]. Specifically, liposome can encapsulate hydrophilic molecules in the aqueous
interior, incorporate hydrophobic molecules in cavities of fatty acid chains, and carry drugs
conjugated on the surface (Figure 1.5). Secondly, because both external and internal surfaces of
the bilayer are outlined by the hydrophilic headgroups of phospholipids, liposomes represent a
colloidal system to stabilize diverse payload molecules in aqueous media. Encapsulated
hydrophilic payload molecules can be protected by the lipidic bilayer from deactivation in
physiological media. Hydrophobic molecules that are incorporated in the liposome membrane
can improve the solubility, stability and bioavailability in blood circulation [69, 89]. Thirdly, due
to their generally biocompatible components, liposomes tend not to inflict severe
immunoreaction or toxicity [90].

Hydrophilic head
Lipophilic tail
Hydrophilic Drugs
Aqueous
interior

Lipophilic Drugs
Surface-conjugated Drugs

Figure 1.5. Schematic of liposome loaded with hydrophilic, lipophilic and surface-conjugated
drugs.
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1.3.4 Liposomal drug delivery and drug release. The pharmacokinetic profile and
efficacy of liposomal drug delivery systems are largely correlated to: a) physicochemical
characteristics including size, surface charge, steric hindrance, stability, and drug loading
efficiency, b) successful delivery of drugs to the targeted sites, and c) successful release of drugs.
Complex mechanisms have been developed to improve the precision of liposomal drug delivery
and drug release, which can occur both extracellularly and intracellularly. The extracellular
delivery by liposomes include passive targeting and active targeting (1.1.2.2). The liposomes are
circulated in blood and then extravasate to accumulate in the interstitium of diseased tissues,
followed by either drug release or endocytosis. Liposomes are often designed to release the
payload more quickly in response to specific signals at the target site (aka triggered release),
such as the acidic pHe in tumors. The intracellular delivery of liposomes is needed for protein
and nucleic acid therapeutics, because those molecules need to reach appropriate subcellular
organelles to exert activity but cannot cross cell membranes by diffusion due to their large size
and high hydrophilicity [91]. One of the major mechanisms of delivering large molecules into
cells is endocytosis, the means of which include clathrinmediated endocytosis, phagocytosis,
micropinocytosis and caveolae-mediated endocytosis. Endocytosis provides a mechanism to
cross the plasma membrane but can result in varying levels of lysosomal degradation and
exocytosis [92]. In order to avert these processes, some liposomal systems are designed to
escape the endosome in response to a local stimuli such as acidic pH and enzymatic activities in
the endosome [93, 94]. Besides endocytosis, lipid-mediated fusion with cell membrane is
another major pathway for liposomes to release drugs into cells [95, 96].
1.3.5 Classification of liposomes. Liposomes can be formulated and processed to differ
in size, lamellarity, composition, and surface charge. Besides these features, various molecules
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can be grafted on the surface of liposomes to cater to various applications in drug delivery
(Figure 1.6). Major classes of liposomes are summarized in Table 1.1.

Table 1.1
Types of liposomes based on size and lamellarity, composition and charge, and application. [97,
98]
Classification
Types
Properties
Principals
With a single bilayer. Size ranges from
Small Unilamellar Vesicles (SUV)
20 to 100 nm
Size and
With a single bilayer. Size ranges from
Lamellarity Large Unilamellar Vesicles (LUV)
100 to 1000 nm

Composition
and Charge

Multilamellar Vesicles (MLV)

With multiple bilayers

Conventional Liposomes

Simply contain neutral/anionic
phospholipids and cholesterol

Cationic Liposomes

Contain cationic lipids such as DOTAP

Stealth Liposomes
Stimulus-sensitive Liposomes
Application
Ligand Targeted Liposomes
Immunoliposomes
Transferosomes
Ethosomes
Pharmacosomes
Emulsomes
Niosomes
Vesosomes
a. C

Contain a PEG coating to improve
circulation time
Physicochemical changes in response to
specific stimuli
Grafted with targeting ligands to
interact with receptors on cells
Grafted with monoclonal antibodies for
targeted drug delivery
With high elasticity to improve skin
permeation following topical delivery
Utilize ethanol’s penetration properties
to improve skin penetration
Contain drugs that bind to
phospholipids to improve their
bioavailability
Contain a solid fat core to improve
stability and entrapment efficiency
Contain nonionic surfactants to improve
oral bioavailability of drugs
Contain multiple compartments with an
external bilayer to protect drugs from
degradation and immune defense
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a. Conventional Liposome

b. Stealth Liposome

c. Multifunctional Liposome d. Ligand Targeted Liposome

Figure 1.6. Schematic of liposome surface modification strategies. (A) Conventional liposomes.
(B) Stealth liposomes (PEGylated liposomes). (C) Multifunctional liposomes. (D) Ligand targeted
liposomes. [99]
1.3.5.1 Conventional liposomes. Conventional liposomes, also referred as the ‘first
generation liposomes”, are usually composed of neutral or anionic phospholipids and cholesterol
[83, 100]. Although their lipid bilayers are similar as biological membranes, they are detected by
the immune system as foreign objects. After administrated through IV injection, conventional
liposomes are recognized and rapidly captured by the reticuloendothelial system (RES), leading
to their quick clearance and short half-life [46]. Conventional liposomes have been utilized for
antiparasitic and antimicrobial drug delivery [101]. Nevertheless, RES becomes the major site of
conventional liposome accumulation, resulting in their minimal effect on cells beyond RES.
Conventional liposomes with larger size showed enhanced RES uptake, especially in the liver,
which elevated the hepatic clearance [102]. Furthermore, conventional liposomes, especially
those without cholesterol, displayed poor stability and poor extravasation after injection, due to
their physical interaction with lipoproteins other serum proteins [83, 103].
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1.3.5.2 Stealth liposomes. In order to overcome the aforementioned drawback of
conventional liposomes, the surface of liposomes was modified to prolong their circulation in
blood. The extended circulation time can be achieved by coating the liposomes with inert,
hydrophilic polymers, such as polyethylene glycol (PEG), which provides a protective shell to
hinder adsorption of serum proteins and elimination by RES. Owing to the PEG coating, the
liposomes are less “visible” to RES, thus earning them the distinction as stealth liposomes [80]
[83]. The hydrophilic PEG is also known to bind with water molecules via hydrogen bonding,
which results in a hydration film that surrounds the liposome to mitigate its interaction with RES
[51]. Moreover, the long chains of PEG surrounding a liposome provide a strong repulsion to
the bilayer of other liposomes and thus prevent liposome aggregation, leading to improvement of
liposome stability [104]. These multiple mechanisms of the PEGylated liposomes help them stay
in the blood circulation for a longer period of time. Stealth liposomes have demonstrated doseindependent and non-saturable kinetics, as well as improved bioavailability [105].
PEG can be introduced onto liposome surface in multiple ways, including a) physical
adsorption onto liposomes, b) covalent binding to liposomes, and c) addition of PEGylated lipids
in the bilayer composition during liposome preparation. Stealth liposomes can be prepared using
various lengths of PEG chains, which can substantially influence the liposome properties.
Generally, the higher molecular weight of PEG leads to longer circulation time, except that liver
clearance is found to be increased when the average molecular weight of PEG goes over 50000
Da [106]. PEG molecules ranging 2000 – 5000 Da have been extensively utilized in the
preparation of stealth liposomes [107]. Besides PEG length, the performance of stealth
liposomes in vivo is also influenced by other physicochemical properties, such as their size. It
was found that 275 nm is the maximum limit of stealth liposome size, beyond which the stealth
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property is significantly compromised [108]. Stealth liposomes with diameter of 100-150 nm
were found to display notably reduced interaction with opsonins and other proteins in plasma
[79, 109, 110].
Stealth liposomes are important in cancer treatment because their properties support
passive targeting of their payload drugs. By minimizing the interaction of with RES, the stealth
liposomes are targeted to tumor tissues more than RES. With PEG functionalization, the half-life
of liposomes in blood circulation was extended from a few minutes to several hours [79]. The
EPR effect is principally correlated to circulating time, and thus can be enhanced in stealth
liposomes thanks to the sufficient time for such liposomes to circulate and to accumulate in
tumor tissues. The preferential accumulation of stealth liposomes in tumor tissues leads to
highly concentrated payload drugs at the target site and hence improvement in therapeutic
efficacy over conventional liposomes.
Despite the prolonged circulation time and improved passive targeting of stealth
liposomes, the steric hindrance of PEG chains decreases the interaction of liposomes with tumor
cells [111], which in turn decreases intracellular uptake of the liposomal drug. To overcome this
challenge, active targeting strategies, either ligand-receptor binding or locally activated drug
delivery, has been applied along with the passive targeting to improve the drug delivery. The
ligand-receptor mediated active targeting can be introduced by modifying the surface of stealth
liposomes with targeting ligands. With the targeting ligands attached, the stealth liposomes
would have significantly more interaction with tumor cells that overexpress the corresponding
receptor [85]. Moreover, because the stealth liposomes can lodge in the interstitial spaces
between the tumor cells, some elaborate targeting ligands were utilized to deliver the liposomes
further into cancer cells [83]. The locally activated targeting can be achieved by incorporating
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molecules that can trigger the liposomes in response to specific local stimuli. Stimulus-triggered
release is the most common mechanism of action by stimulus-sensitive systems.
It must be noted that long circulation time is not always desirable for liposomes because
it may also cause additional toxicity other than that of the cytotoxic payload [98]. For example,
Doxil®, the approved stealth liposomal DOX, has much longer half-life (2-3 days) than free
DOX (0.2 hour). The prolonged circulation time and passive targeting makes Doxil a suitable
medicine for skin treatment of localized cancers such as Kaposi’s sarcoma [83]. However,
despite its significantly lower cardiotoxicity, myelosuppression and nausea than free DOX, Doxil
has other significant side effects, such as Palmar-plantar erythrodysesthesia (PPE) and mucositis
[81], which are largely attributed to its reduced clearance and tendency to accumulate at the skin
[112]. In contrast, Myocet™, the approved conventional liposomal DOX with a much shorter
half-life (2-3 hours) is not associated with PPE and has remarkably reduced incidence of
mucositis [113]. Still, Myocet has sufficient circulation time to allow effective passive targeting
to tumor sites, as demonstrated in studies on its use against metastatic breast cancer [80]. Stealth
liposome-based and conventional liposome-based delivery systems are both under heavy
development and have both yielded approved nanomedicines. These two types of liposomes are
used to treat different diseases due to their different features so neither one would be able to
substitute the other.
1.3.5.3 Stimulus-sensitive liposomes. Triggered release is a strategy to enhance the
payload drug exposure to target cells and hence to improve the therapeutic outcome of liposomal
formulations [114]. To achieve triggered release, liposomes are functionalized with specific
molecules, thus become sensitive to target-specific stimuli and can release the cargo agents upon
activation by those stimuli, which can be either internal or external.
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The internal stimuli are endogenous signals that are specifically presented at or near the
diseased sites, including pH, redox potentials, temperature, and enzymes. The pH gradients in
tumor interstitium and endosomes have been widely utilized to trigger extracellular and
intracellular release of payload agents from pH-sensitive liposomes [23, 114]. Liposomes can
also be triggered in tumor tissues by their lower redox potential due to their hypoxia condition
[60]. Thermo-liposomes can elevate their drug release when stimulated by higher temperature in
inflammatory tissues [115] or by hyperthermia treatment of tumors [116]. In endosomes,
hyaluronidase, the enzyme that degrades hyaluronic acid (HA), can trigger endosomal escape of
HA-coated liposomes [94].
The external stimuli include ultrasounds, light, magnetic field and electric field. Such
stimuli are applied for spatiotemporal control. It was found alternating magnetic field (AMF)
can trigger the self-heating of liposome-encapsulated iron oxide nanoparticles to permeate the
liposome membrane and hence to enhance the content release [117]. Ultrasound was found to
expand gas pockets and thus was used to permeate the membrane of liposomes that coencapsulate drugs and gas bubbles [118].
1.3.5.4 pH-sensitive liposomes. pH-sensitive liposomes have been developed to respond
to the change of pH in specific biological microenvironments. pH gradients in the body have
been investigated as an internal stimulus for drug delivery systems. The gastrointestinal (GI)
track has a broad range of pH, from 1-3 in stomach, to 6 in duodenum, and to 7-8 in jejunum and
ileum [119]. The tumor tissues have lower pHe than normal tissues (pH 7.4), ranging from 5.8 to
7.6 and averaging around 7.0 [14]. The highly hypoxic core in tumors generally displays pHe
6.1-6.4 [15]. pH decrease is also found during endosome maturation: from 7.4 to 6.5 in early
endosomes, then to 5.5 in late endosomes, and then to 4.5 in lysosomes [120].
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Figure 1.7. Schematic of two levels of pH-triggered responses of liposomes. (a) pH-triggered drug
release in tumor interstisium [121]. 1) Liposomes are not able to extravasate to healthy tissues. 2)
Liposomes extravasate to tumor tissues through the more porous tumor blood vessels. 3)
Liposomes are retained in the tumor microenvironment. 4) Triggered release in response to acidic
pH in tumor interstitium. (b) pH-triggered endosomal escape in cytoplasm [122]. 1) Direct fusion
pathway of liposomes. 2) Endocytosis pathway of liposomes. 3) Maturation process of endosomes.
4) pH-Triggered endosomal/lysosomal escape.
Mechanistically, pH-sensitive liposomes undergo rapid destabilization in acidic
environments to exert their biological activities [114]. The methods of inducing pH-sensitivity
include incorporation of pH-sensitive lipids (such as DOPE or synthetic novel lipids) in the
liposome membrane, conjugation with pH-sensitive molecules such as polymers and peptides,
and encapsulation of pH-sensitive substances such as nanoparticles and peptides [23]. The pHtriggered actions of liposomes include content release, interactions with cells (such as binding,
membrane fusion, and endocytosis), and endosomal escape. For some examples, pH-induced
conformational flip of cyclohexane ring was utilized to produce a novel pH-sensitive lipid, which
can permeate liposome membranes when exposed to the acidic microenvironment in tumor
interstitium, thereby enhancing the release of the cargo drugs [123]; pH-sensitive alkylated Nisopropylacrylamide (NIPAM) copolymers enhanced the liposomal release after being grafted
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onto liposome surface as a polymer coating [124]; magnesium phosphate nanoparticles that were
co-encapsulated in liposomes were found to dissolve at lowered pH in endosomes to increase the
osmotic pressure, which in turn help the cargo agents to escape the endosome [93].
1.3.6 Imidazole-based convertible liposomes (ICL). Although the PEG coating of
liposomes helps to overcome the short circulation time and RES clearance to enhance tumor
accumulation, the steric hindrance of the PEG coating also reduces the liposome’s interaction
with the cancer cells [125]. An ideal liposomal formulation is expected to carry not only high
stability and sufficient accumulation in tumor tissues, but also good interaction with cancer cells
to improve their penetration into solid tumors and their cargo’s intracellular uptake. If a
liposome carries the PEG coating in blood circulation and yet removes the coating upon
exposure to cancer cells, then it can first accumulate at tumor sites and then interaction with
cancer cells. Specific stimuli from tumor sites, such as acidic pH, can trigger this conversion.
Previously, various PEG-shedding strategies were reported [126]. pH-sensitive linkers that can
be hydrolyzed at acidic pH were used to detach the PEG molecules from liposome surface.
However, such hydrolysable liposomes showed either poor stability at physiological pH 7.4 or
insufficient pH-sensitivity at the mildly acidic pH 6.0 in tumor interstitium. Recently, our group
developed a novel pH-sensitive liposome, whose grafted PEG chains are clustered rather than
shed at acidic pH, is expected to be stable at physiological pH 7.4 but also activated to improve
interaction with cancer cells in acidic tumor interstitium (Figure 1.8).
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Figure 1.8. Schematic of two strategies to reduce the steric hindrance of PEG coating of stealth
liposomes at acidic pH: PEG shedding (right upper) and PEG clustering (right lower).
Instead of using hydrolysable linkers to shed the PEG coating at acidic pH, this novel
liposome contains 25 mol% of a synthetic lipid with an imidazole headgroup and two C16
hydrocarbon chains, which can protonate to display positive charges in response to acidic pH
(Figure 1.9). This novel liposome also consists of DPPE-PEG (5 mol %), which is a PEGylated
C16 phospholipid with a negative charge on the Phosphatidylethanolamine (PE) headgroups.
The liposome also consists of a neutrally charged C18 phospholipid DSPC (70 mol %) (Figure
1.9). Due to electrostatic attraction between the headgroups and Vander Waals forces between
the lipid tails of the same length [127], the positively charged imidazole-based lipids (C16) can
cluster with the negatively charged DPPE-PEG (C16) (Figure 1.8) to expose part of the liposome
surface free of PEG coating to interact with cancer cells. Moreover, the protonated imidazolebased liposomes display excess positive charges to interact more with cell membranes, which are
negatively charged [128] (Figure 1.10). Such novel liposomes would show the stealth properties
at physiological pH 7.4 but converts into cationic liposomes at acidic pH in tumor interstitium.
Such liposomes are named imidazole-based convertible liposomes (ICL) [129].
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Figure 1.9. Chemical structures of lipids that constitute ICL: (1,2-dipalmitoyl-sn-glycero-3phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 (DPPE-PEG) (C16, negatively
charged), the imidazole based lipids DHI/DHMI/DHDMI (C16, positively charged at acidic pH),
and 1,2-distearoyl-snglycero-3-phosphocholine (DSPC) (C18, neutral). At acidic pH, the
imidazole-based lipids would be protonated and cluster with DPPE-PEG due to the electrostatic
interaction.
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Figure 1.10. Schematic of ICL turning from stealth liposomes into cationic liposomes. ICL
contains negatively charged DPPE-PEG (shown by ‘P’), imidazole lipids (shown by ‘N’), and
neutral DSPC. In blood circulation (at pH 7.4), the ICL are coated with a PEG shell to prolong
their circulation time (left). When the ICL are delivered into tumor tissue (at pH 6.0-7.0), the
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(Figure 1.10 Continued)
imidazole lipids are protonated (shown by ‘N+’) and therefore cluster with DPPE-PEG to expose
a domain with excess positive charges and without the PEG shell. Such cationic liposomes would
have greater interaction with cancer cells.
1.4 3D Multicellular Spheroids (MCS)
1.4.1 2D and 3D cell culture systems. Traditionally, the in vitro processes which are
used to assess the activity of anticancer drug are two-dimensional (2D) monolayer cancer cells.
Besides cancer research, 2D cell culture systems have also been broadly applied in other fields of
biological and medical sciences, such as basic cellular research, stem cell research and
regenerative medicine. 2D cell culture systems have many advantages, including high efficiency,
low cost and convenient operation. However, the 2D monolayers cell culture cannot adequately
simulate many features of solid tumors, such as cell-cell interactions, tissue hypoxia and ECM
[130, 131]. It has been found the 2D cell culture systems are not always predictive of the clinical
performance of new drug candidates. Poor correlation is also noted between the outcomes from
2D monolayer cell models in vitro and on those from animal models in vivo. Because 2D
monolayer cells lack the solid structures or the complex dynamics of material transport in real
tumors, they are also substantially different in many other functions such as proliferation and
responses to external stimuli [132].
However, in vitro cell culture models are still widely used because of their low cost and
high efficiency, especially in high throughput screenings (HTS) [133]. Three-dimensional (3D)
cell cultures allow the cells can grow and interact with their surroundings in all three dimensions,
similar to how they would in vivo [134]. 3D culture systems are usually conduced in small
capsules or bioreactors where the growing cells would form spheroids or 3D cell colonies. 3D
cell culture systems have been used in research since 1970s but are emerging as attractive in vitro
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models for drug discovery owing to their huge translational potentials [135, 136]. The
establishment of 3D cell culture models is focused on the physiologically relevant multicellular
structures and the ECM, which is more relevant than 2D cell culture systems for validating cell
responses to therapeutics. 3D cell culture models are able to resemble not only the 3D
morphology of solid tissues but also the complex tissue properties including cell connectivity,
tissue architecture, and even gene expression, all serving to better bridge between in vitro and in
vivo models.
Among the 3D models, multicellular spheroids (MCS) are the most accessible,
economical and versatile due to their diverse and relatively simple preparation methods [136].
3D MCS, also known as spheroids, are spherical constructs composed of self-assembled cells.
Many 2D monolayer cell cultures have been adapted to construct spheroids systems, including
multicellular tumor spheroids (MCTS), neurospheres, mammospheres, hepatospheres and
embryoid bodies [133, 137]. Besides cancer research, 3D cell culture techniques have also been
commonly applied to stem cell research and tissue engineering.
1.4.2 Similarity between MCTS and solid tumors. The best-characterized 3D cell
culture technique in anticancer research is MCTS, which is derived from cancer cell lines
commonly used in 2D culture [138]. MCTS are more representative in vitro models of solid
tumors than 2D monolayer cells, due to their solid morphology, gradients of oxygen, nutrients
and pH, heterogeneous cell viability, cell-cell interaction, and complex ECM [138, 139]. Owing
to the above biological features, MCTS have been utilized to study solid tumor biology and to
establish platforms to screen for anticancer drugs.
1.4.2.1 Three gradients and three layers of cell organization. Similar with in vivo solid
tumors, MCTS have three gradients – oxygen, nutrients, and pH gradients, and a three-layer cell
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organization – proliferating, quiescent, and necrotic cell layers. Owing to the dense solid
constructs of aggregated cells, penetration of oxygen and nutrients are limited in MCTS. The
hypoxic characteristic of MCTS has been well adapted to assess oxygen-dependent therapeutics.
For example, many studies explored the sensitivity of MCTS to radiation in order to effectively
predict the clinical responsiveness of solid tumors to radiotherapy, because hypoxia was found to
be a major contributor to the radio-resistance of tumor cells [140, 141].
The pH gradients in MCTS are attributed to insufficient penetration of oxygen and
nutrients. Without adequate oxygen and nutrients, metabolic pathways in MCTS to favor
anaerobic metabolism while the removal of metabolic waste is enfeebled, jointly leading to an
accumulation of metabolic by-products of hypoxia, mostly lactate [142]. Thus, similar with solid
tumors, MCTS carry acidic interstitial pH, especially in the core. Such lowered pH of MCTS
allows better understanding of tumor biology and better evaluation of anticancer therapeutics.
The vasculature-free “microtumors” mimicked by MCTS are composed of three layers of cells proliferating cells at the periphery, quiescent cells right below the proliferating cells, and necrotic
cells in the MCTS core. Such a three-layer cellular structure of MCTS is similar to the avascular
regions in solid tumors (Figure 1.11) [22]. The three-layer cell organization of MCTS is closely
correlated to the gradients of oxygen, nutrients and pH, and primarily relies on the volume and
growth rate of spheroids. MCTS larger than 500 µm were found to assume this three-layer cell
organization [143, 144]. MCTS with diameter below 120 µm were found well oxygenated, but
as they grow larger, the concentrations of oxygen and nutrients in the inner core decrease rapidly.
Subsequently, the MCTS interstitial pH also decreases, followed by the decrease of cell viability
[145]. Both the hypoxia and the necrosis characteristics of MCTS closely mimic their
corresponding gene expression profiles in solid tumor [146].
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Figure 1.11. Schematic representation of bio-similarity between MCTS (left) and solid tumor
(right). [22]
1.4.2.2 ECM, cell-cell and cell-ECM interactions. The extracellular matrix (ECM) is a
major structural component in tumor microenvironment. ECM contains proteins and
polysaccharides to provide cells with essential physical and biochemical support. The traditional
2D monolayer cell cultures cannot mimic the microenvironment in solid tumors because of their
much weaker cell-cell and cell-ECM interactions, which often makes them unreliable models to
evaluate drug efficacy and toxicity [147]. The in vivo-like MCTS models would overcome some
of these limitations. Various types of ECM components, including structural (collagen and
elastin) and adhesive (fibronectin and laminin) proteins, are found in MCTS in similar
proportions as those in solid tumors. Such components have been found as critical factors to
define the interaction between MCTS and drugs [148, 149]. Because of the importance of ECM
to cell survival, proliferation, and migration, MCTS have been utilized to investigate not only the
mechanisms of cell migration and invasiveness in tumors but also the therapeutics applied to
prevent them [150]. The ECM components in MCTS depend on the cell lines and techniques of
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MCTS construction. Some cancer cells can produce adequate ECM substrates for selfassembling while some cancer cells cannot [151]. Cancer cells that do not produce sufficient
ECM substrates can be assisted by scaffold materials to establish their MCTS. Biocompatible,
natural polymers such as collagen, fibrin and Matrigel are utilized as scaffolds to construct ECMembedded MCS models because those polymers intrinsically contain ECM components,
including growth factors (GFs) and laminin [136]. Despite the advantages of 3D MCTS over 2D
cell culture from their ECM, it should be noted that the ECM substrates in MCTS originate
differently compared to those in solid tumors in that the former are generated by cancers cells or
added extrinsically, while the latter are secreted by fibroblasts [152]. To better study the cellECM interactions in tumors as well as their impact on anticancer treatments, MCTS co-cultured
with stromal components (e.g. fibroblast, macrophages and endothelial cells) have been
developed as the more in vivo-like models that mimic the heterogeneity of tumor tissues [153].
1.4.2.3 Drug penetration and drug resistance. 3D MCTS models have become more
predictive tools for drug screening because they can mimic the restricted intratumoral drug
penetration, which is a large contributor for drug resistance in vivo [137]. The microenvironment
forcell-cell and cell-ECM interactions in MCTS closely mimics the permeability barriers in solid
tumors [149]. Moreover, the hypoxic regions seen in both solid tumors and MCTS was found to
limit the penetration of anticancer drugs by boosting their local degradation/metabolism [154,
155]. Drug penetration into MCTS was studied under tunable hypoxic conditions that were
controlled by extrinsic hypoxia-reoxygenation cycling, which showed poor drug penetration into
hypoxic spheroids and increased penetration and cellular uptake of drugs in reoxygenated
spheroids [156]. Together, hypoxia, necrosis and acidic pH all contribute to drug resistance in
solid tumors, which are all replicated in MCTS but not in 2D cell culture [13].
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3D MCTS should greatly benefit the development and clinical translation of anticancer
nanomedicines due to their unique physicochemical properties. MCTS provide a solid construct,
which can provide the in vivo-like interaction with nano drug carriers. Because the
physicochemical properties (size, shape, surface, etc) of nano drug carriers greatly affect their
interaction with tumor cells, such properties can be optimized according to their effects in MCTS
models [157, 158]. MCTS also contains ECM which provides highly in vivo-like physical and
biochemical barriers for nanomedicines. Nanomedicines can be designed and developed to
overcome such impediment from ECM based on the in vitro data from the ECM of MCTS.
Lastly, MCTS containing ECM stromal cells are considered even more clinically relevant. For
example, Doxil® was reported to have reduced penetration into MCTS of breast cancer cells
when the MCTS also contains fibroblasts [159].
1.4.3 3D cell culture techniques. 3D cell culture can be constructed by many
techniques, which can be grouped into scaffold-based techniques and scaffold-free techniques.
1.4.3.1 Scaffold-based techniques. Scaffold-based techniques are also known as matrixbased techniques, which refer to the utilization of solid scaffolds, hydrogels and other materials
to provide the structural support. For example, hydrogels, which provide high moisture retention
and interconnected pores, allows adequate gas exchange and nutrient supply in a way similar to
natural ECM structures in tissues [160]. Agarose gel was used to generate a 3D model to
understand the bone ossification process and potential of human CD34+ stem cells. Scaffolds
can also play as vehicles to control the delivery of drugs, proteins and DNA [151, 161].
Scaffold-based 3D cell culture still faces several challenges, including poor initial cell
density in the constructed tissues, and improper usage of scaffold materials [162]. Some
scaffolds may interfere with the behavior of the cells such as their interaction with drugs. Some
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scaffolds may also induce biodegradation, which is triggered by inflammatory responses of the
cultured cells. Scaffolds with too small pores would limit transport of oxygen, nutrients, and
waste, resulting in poor cell survival and proliferation. The surface properties of scaffold
materials would also affect cell adhesion, proliferation, aggregation, and functions [163]. Taken
together, significant factors to consider when choosing scaffold materials include their cell
interaction, porous size, and surface properties. Matrix materials such as Matrigel and HA are
considered as ideal scaffolds for 3D cell culture, which are biocompatible and can provide
growth factors and signal factors to promote cell proliferation [137, 164].
Scaffold-based techniques have been extensively applied in tissue regeneration and cell
transplantation. They have limited capability to construct 3D MCS, due to the inhomogeneous
distribution of cells seeded in the porous scaffold and the lower initial seeding density compared
with scaffold-free techniques [165]. However, the scaffold-free methods with the addition of
scaffold/matrix materials, such as collagen and Matrigel, have been extensively applied to
construct MCS tumor models using cancer cells that produce limited ECM substrates [136, 166].
1.4.3.2 Scaffold-free techniques. Scaffold-free techniques are methods to construct 3D
culture models without dependence on scaffold materials. This strategy relies on the inherent
ability of the culturing apparatus to assemble cells into larger structures [165]. Available
scaffold-free methods (Figure 1.2) include hanging-drop, forced-floating (low adhesion surface),
agitation-based bioreactors (spinning flask and rotating culture), force-driven approaches
(magnet, electric and acoustic), cell sheets and bioprinting [137, 164].
Scaffold-free techniques have been developing faster than scaffold-based techniques due
to a number of advantages[167]. With external rigid support, scaffold-free techniques can
overcome the challenges of scattered cells to construct solid 3D assemblies. It takes less time to
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construct 3D models by scaffold-free methods because the initial cell seeding density is much
higher than scaffold-based methods. Consequently, cell proliferation and migration are not
crucial factors for the 3D MCS construction. Compared with time-consuming scaffold-based
methods, which use scaffold materials that may be biodegradable, scaffold-free methods are
considered as faster, safer, and more reliable techniques [168].
Furthermore, scaffold-free methods have been used to construct not only 3D MCS of one
type of cells but also those of multiple types of co-cultured cells in order to simulate the
complexity of tissue and organ architecture [167]. Some 3D co-culture spheroids are composed
of both cancer cells and other cells known to be involved in tumor progression, such as
fibroblasts, macrophages, monocytes, endothelia and immune cells. Such co-culture MCTS can
provide more pertinent assessments of anticancer therapeutics [153, 169, 170].
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Figure 1.12. Common methods to construct 3D MCS. (a) Low adhesion plates. (b) Hangingdrop. (c) Spinning flask. (d) Rotating culture. [164]
1.5 Hypothesis and Specific Aims.
Based on the foregoing, the hypothesis of this thesis is that compared with conventional
stealth liposomes, the convertible liposomes with pH-sensitivity introduced by the imidazole-
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based lipids can express better anticancer activity in vitro. To test this hypothesis, this project
has the following specific aims:
1. To prepare, optimize and characterize the imidazole-based convertible liposomes (ICL).
2. To test the pH-sensitivity of ICL.
3. To study the morphology of ICL using transmission electron microscopy (TEM)
4. To evaluate the anticancer activity of ICL on 3D multicellular spheroids (MCS).
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CHAPTER 2: PREPARATION AND PHYSICOCHEMICAL CHARACTERIZATION OF
IMIDAZOLE-BASED CONVERTIBLE LIPOSOMES

2.1 Introduction
Liposomal formulations have been reported to carry considerable advantages, including
high loading capacity of drugs, capability to carry either hydrophilic or lipophilic payload drugs,
relatively long half lives in blood circulation, and targeting to tumors [171]. The stealth liposomes,
which contain PEGylated lipids to form a surface coating of the PEG polymers, can achieve longer
half-life in blood circulation than conventional liposomes by sterically hindering their recognition
by reticuloendothelial system (RES) [172]. The increased half-life allows the stealth liposomes to
accumulate more in the perivascular environment in solid tumors, a phenomenon known as the
enhanced permeation and retention (EPR) effect. However, the steric hindrance of the PEGylated
stealth liposomes also decreases their interaction with cancer cells [125]. To increase the liposomecancer cell interaction and thus to improve the intracellular delivery of the payload drug, three
imidazole-based ether lipids were developed in our group to be protonated at the acidic
microenvironment of the tumor interstitium. At acidic pH, the PEGylated stealth liposomes
containing the imidazole-based lipids would convert to cationic liposomes, thus given the name
imidazole-based convertible liposomes (ICL). The cationic liposomes thus formed at acidic pH in
the tumor microenvironment would then better interact with the negatively charged cell membrane
[40].
The studies reported in this chapter aim to develop more robust methods to prepare DOXloaded ICL for anticancer drug delivery. Various PEGylated liposomes containing imidazolebased ether lipids were constructed to investigate the effect of multiple factors on the
physicochemical properties of ICL and to discover more robust methods of preparing ICL.
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2.1.1 Design of the imidazole-based ether lipids. The imidazole headgroup has been
chosen to conjugate with the two C16 hydrocarbon chains due to its unique properties. The N3 of
the imidazole moiety is basic (estimated pKa 5.5-6.8) and thus would protonate at mildly acidic
pH. The protonation of imidazole would then provide positive charges to the lipid molecules,
which would then interact with the negatively charged PEGylated lipid molecules. The imidazole
lipids and the PEG-lipid conjugate (DPPE-PEG) all carry C16 hydrocarbon chains to further
enhance their Van Der Waals interactions.

DHI

DHMI

DHDMI
Figure 2.1. Structures of the imidazole-based ether lipids.
2.1.2 The composition of ICL. The imidazole-based convertible liposomes (ICL)
contain DSPC (C18), imidazole-based lipids (C16) and DPPE-PEG (2000) (C16). In our studies
that investigated the influence by cholesterol, 25% cholesterol were added in place of the same
mole percentage of DSPC. ICL were studied in comparison with a non-sensitive liposomes
(NSL), which contains no imidazole-based lipids. The lipid composition of ICL and NSL without
and with cholesterol are shown in Table 2.1.
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Table 2.1
Lipid composition of ICL and NSL formulations without and with cholesterol
Mol %
Formulations

DHI

DHMI

DHDMI

DSPC

DPPE-PEG

Chol

I

25

-

-

70

5

-

II

-

25

70

5

-

III

-

-

25

70

5

-

IV

-

-

-

95

5

-

V

25

-

-

45

5

25

VI

-

25

-

45

5

25

VII

-

-

25

45

5

25

VIII

-

-

-

70

5

25

2.1.3 The phase transition temperature of ICL. The phase behavior of lipid bilayers
has been widely acknowledged as property about the mobility of individual lipid molecules in
response to temperature [173]. Generally, a lipid bilayer can exist in either gel phase or fluid
phase at a certain temperature. The gel phase is commonly known as lipid bilayers composed of
lipids in solid state. The fluid phase, also known as the liquid crystal phase, is known as lipid
bilayers composed of lipids in liquid state. Same as in gel phase, the lipid molecules in fluid
phase bilayers are constrained to the lateral plane of membranes. However, the lipid molecules
in the fluid phase, but not those in the gel phase, have free lateral diffusion within their
monolayer. The temperature at which a specific lipid transits from the ordered gel phase to the
disordered fluid phase is defined as its phase transition temperature (Tm) [174]. The Tm value of
a lipid was found to be a function of the length of its acyl chains and its saturation [175]. Table
2.2 shows that phospholipids with longer acyl chains and less unsaturated bones bonds would
possess higher Tm.
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Table 2.2. Hydrocarbon length, unsaturated and Tm of lipids with PC and PE headgroups [176]
Lipids

Length of Acyl Chains

Unsaturated Bones

Tm (˚C)

DLPC

12

0

-2

DMPC

14

0

24

DPPC

16

0

41

DSPC

18

0

55

DOPC

18

1

-17

DLPE

12

0

29

DMPE

14

0

50

DPPE

16

0

63

DSPE

18

0

74

DOPE

18

1

-16

According to Table 2.2, the Tm of DSPC and DPPE are 55˚C and 63˚C, respectively. The
Tm of a liposomal bilayer is determined by the Tm of the component lipids [177]. Concisely, Tm
of a bilayer system was defined as the temperature at which half of the substance is in its fluid
state, while the other half is in its gel state [177]. The shift of Tm of a lipid bilayer after
incorporation of PEGylated lipids can be attributed to the mismatch of acyl chain length and the
negative effect of PEG [178]. For PEGylated lipids containing shorter polymers (up to 3000),
their acyl chains determine their effect on the Tm, while for PEGylated lipids containing longer
polymers (> 3000), their PEG chains determine their effect on the Tm. Accordingly, the Tm of
DPPE-PEG (2000) should be close to the Tm of DPPE (63˚C). The Tm of imidazole-based lipids
(C16) is estimated to be lower than that of DSPC (55˚C), due to their shorter acyl chains. Based
on the foregoing, we estimated that the Tm of our ICL liposomal bilayer would be around 63˚C.
Therefore, the temperature during the ICL preparation was set at 70˚C to ensure that the bilayer
was to be completely kept in the fluid phase.
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2.2 Materials and Methods
2.2.1 Materials. 1,2-Di-O-hexadecyl-rac-glycerol (DHG), 2- Mercaptoimidazole, 4Methyl-1H-imidazole-2-thiol and 4,5-Dimethyl-1H-imidazole-2-thiol were purchased from
Santa Cruz Biotechnology (Dallas, TX, US). pToluenesulfonyl chloride, dichloromethane
(anhydrous), pyridine (anhydrous), DMF (anhydrous) and 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) were purchased from Fisher Scientific (Hampton, NH, US).
Triethylamine (TEA) and Silica Gel 60 (230-450 mesh) were purchased from Alfa Aesar
(Haverhill, MA, US). The lipids 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2dipalmitoyl-snglycero-3-phosphoethanolamine-N-[azido(polyethylene glycol)-2000 (DPPE-PEG
(2000)), and 1,2 dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) were purchased from Avanti
Polar Lipids, Inc. (Alabaster, AL, USA). Cholesterol, Dowex® 50WX-4 (50-100 mesh), and
Sephadex G-25 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Doxorubicin
Hydrochloride was purchased from Biotang (Waltham, MA, USA). All other organic solvent
and chemicals were purchased from Sigma Aldrich, Fisher Scientific or VWR.
2.2.2 Synthesis of imidazole-based ether lipids.
2.2.2.1 Synthesis of 1,2-Di-O-hexadecyl-rac-glyceryl tosylate (DHG Tosylate). 1,2-DiO-hexadecyl-rac-glycerol (DHG) (2.30 g, 4.25 mmol, 1 equiv) was dissolved in 20 mL
anhydrous dichloromethane, coupled with pyridine (18.6 mL, 225 mmol, 50 equiv). pToluenesulfonyl chloride (1.90 g, 9.97 mmol, 2 equiv) was dissolved in small amount of dry
dichloromethane and transferred to the above solution. The apparatus and solid reagents were
dried under high vacuo at room temperature for over 4 hours the dry solvents and solutions were
transferred by Hamilton syringe or double-pointed needles under argon. The reaction mixture
was stirred under argon at room temperature for 8 to 12 hours. The reaction was monitored by
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silica gel TLC (Fisher Scientific, Hampton, NH, US) using dichloromethane as the mobile phase.
The reaction mixture was then mixed well with 10 ml anhydrous dichloromethane and washed
with saturated sodium carbonate solution for 3 times. The organic phase was separated from the
aqueous phase and was then dried with magnesium sulfate. The dried solution of the reaction
mixture was filtered and then evaporated into dryness under vacuum. The resultant residue was
then seperated by silica gel chromatography with dichloromethane as the mobile phase to yield
2.53 g DHG-tosylate solid. (Yield 86%).
2.2.2.2 Synthesis of sn-2-((2,3-bis(hexadecyloxy)propyl)thio)-1H-imidazole
(DHI), sn-2-((2,3-bis(hexadecyloxy)propyl)thio)-5-methyl-1Himidazole (DHMI) and sn-2((2,3-bis(hexadecyloxy)propyl)thio)-4,5-methyl-1Himidazole (DHDMI). In order to achieve the
anhydrous conditions for the reactions, the glass apparatus and reagents were pre-dried in high
vacuum for over 4 hours, and transfers of liquid were handled by air-tight Hamilton syringe and
double-pointed needles under argon. 2- Mercaptoimidazole (0.91 g, 9.06 mmol, 5 equiv.), 4Methyl-1H-imidazole-2-thiol (1.03 g, 9.03 mmol, 5 equiv.), or 4,5-Dimethyl-1H-imidazole-2thiol (1.15 g, 9.03 mmol, 5 equiv.) was dissolved in 8-9 mL N,N-Dimethylformamide (DMF).
DHG-tosylate (1.265 g, 1.82 mmol, 1 equiv) was dissolved in 7-8 ml of dry dichloromethane and
transferred into the above-mentioned solution, followed by addition of Triethylamine (TEA)
(1.27 mL, 9.08 mmol, 5 equiv.). The reaction mixture was stirred under argon at 55˚C for 48
hours. The reaction was monitored by TLC (silica gel plate) and UV with 5/95 (v/v)
methanol/dichloromethane or ethyl 3/7 (v/v) acetate/hexane as the mobile phase. The solvent
was evaporated under vacuum and the resultant residue was dissolved in dichloromethane. The
solution was washed with saturated sodium bicarbonate solution for 3 times, dried with sodium
carbonate, filtered and then evaporated into dryness under vacuum. The resultant residue was
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then separated by silica gel chromatography with 1-5% (v/v) methanol/dichloromethane as the
mobile phase to yield DHI, DHMI and DHDMI. (Yield 25-30%).

DHI
DHMI
DHDMI

R1 = H, R2 = H
R1 = H, R2 = CH3
R1 = CH3, R2 = CH3

Figure 2.2. Synthesis of imidazole-based lipids DHI, DHMI and DHDMI.
2.2.3 Preparation of ICL formulations.
2.2.3.1 Preparation of liposomes. Generally, the liposomes were prepared using film
hydration, freeze-anneal-thawing and extrusion methods. A dichloromethane solution of
imidazole-based ether lipids and a chloroform solution of other lipids were mixed in a recovery
flask. The organic solvents were evaporated under reduced pressure to form a lipidic film on a
Buchi rotavapor at 70˚C. The lipidic film was further dried in vacuum for over 4 hours at room
temperature to remove the residual solvent completely. The lipidic film was then hydrated with
isotonic HEPES buffer (pH 7.4, 5 mM HEPES, 140 mM NaCl) by intermittent agitation in a
70˚C water bath to obtain a liposomes suspension containing 20 mM total lipids. The flask was
filled with argon and sealed with parafilm. The Liposome suspension was freeze-anneal-thawed
by rapidly freezing in liquid nitrogen, emerging in ice-water mixture for 2 min and incubating in
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70˚C water bath for 4 min. The freeze-anneal-thawing was repeated for 11 times. The liposome
suspension was sequentially extruded 21 times each though 400 nm, 200 nm and 100 nm
polycarbonate membranes (Nucleopore Corp., Pleasanton, CA, US) using a hand-held Miniextruder (Avanti Polar Lipids Inc., Alabaster, AL, US) at 70° C to reduce and homogenize the
sizes of liposomes. The resultant liposome suspensions were stored at 4˚C in glass vials filled
with argon and sealed with parafilm until further studies.
2.2.3.2 DOX loading into liposomes by manganese sulfate gradient. The
transmembrane manganese sulfate gradient was used to load DOX into liposomes. The lipidic
film in 2.2.3.1 was hydrated with HEPES buffer (pH 7.4, 30 mM HEPES) containing 300 mM
manganese sulfate by intermittent agitation in a 70˚C water bath to obtain a liposomes
suspension containing 20 mM total lipids. The freeze-anneal-thawing and extrusion were similar
as mentioned in 2.2.3.1. To establish the transmembrane gradient, the extruded liposomes were
separated from the unencapsulated manganese sulfate by size exclusion chromatography (SEC)
using a Sephadex G-75 column (Sigma Aldrich, St. Louis, MO, USA)) pre-equilibrated with
isotonic HEPES buffer (pH 7.4, 5 mM HEPES, 140 mM NaCl). DOX (0.75-3 mg/ml) dissolved
in the same isotonic HEPES buffer was then mixed with the purified liposome suspension
(approximately 10 mM total lipids) in 1:2 (v/v) ratio and mixture was incubated at 70˚C water
bath for 90 min. The cation-exchange resin Dowex® 50WX-4, 50-100 mesh (Sigma Aldrich, St.
Louis, MO, USA) was converted to the sodium form by sequential washing with 400 ml 2 M
NaOH per 100 g of dry resin on filter paper with a Buchner funnel. The NaOH was removed by
washing with 1 M NaCl until the pH returned to neutrality. The resin was then washed several
times with 0.9% (w/v) NaCl and dried overnight on filter paper in vacuum and stored at room
temperature. Such pretreated resin was then mixed with the DOX-liposome mixture at DOX:
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resin = 1:60 (w/w) and shaken on an orbital shaker (Thermo Fisher Scientific, Waltham, MA) at
approximately 100 rpm, room temperature for 25 min to remove the unencapsulated DOX from
the DOX-loaded liposomes. The resin was then separated from the DOX-loaded liposomes by
filtration through glass wool in a syringe. The resultant DOX-loaded liposome suspension
(approximately 7 mM total lipids) was stored at 4˚C in an amber glass vial filled with argon and
sealed with parafilm until further studies.
2.2.4 Physicochemical characterizations of liposomes.
2.2.4.1 Size measurement. An aliquot (2.5-5 μL) of a liposome suspension was diluted
in 150 μL DI water or isotonic buffer and the sizes of liposomes were measured at room
temperature by dynamic light scattering (Zetasizer ZS90, Malvern Instruments Ltd., UK). The
size values are analyzed from the intensity of hydrodynamic diameters.
2.2.4.2 Quantitation of payload DOX concentration and liposome encapsulation
efficiency (EE). An aliquot (10 μl) of DOX-loaded liposome suspension was lysed with 90 μL
lysis buffer (90% (v/v) isopropanol, 0.075 M HCl) [179] in a 96-well Black Clear Bottom
Polystyrene microplate (Corning®, NY, US), together with 10 μL DOX standard solutions (1, 2,
5, 10, 20, 50, 100 μg/ml) diluted in the same lysing buffer (90 μL). All samples in the
quantitation were triplicated. The microplates were covered with foil, and the fluorescence of
the samples was measured at 486 nm (excitation) and 590 nm (emission) on a Synergy HT
microplate reader (Biotek, Winooski, VT, US). Concentration of the payload DOX of liposomes
was estimated using a standard calibration curve from the fluorescence of the above-mentioned
DOX standard solutions. The encapsulation efficiency (EE) of the liposomes was then calculated
by the following formula.
𝐸𝐸 =

𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝐷𝑂𝑋 𝐶𝑜𝑛𝑐.
× 100%
𝐼𝑛𝑝𝑢𝑡 𝐷𝑂𝑋 𝐶𝑜𝑛𝑐. 𝑓𝑜𝑟 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔
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2.2.5 Concentrating the liposome formulations. The DOX-loaded formulations need
to be concentrated before testing on biological systems if their DOX concentration are not
sufficient for the treatment. A diafiltration column (MicroKros®, Spectrum, Stamford, CT, US)
was used to concentrate the liposome suspension by partially removing the extra-liposomal
buffer. The liposome suspension was slowly extruded by two syringes through the diafiltration
column to be condensed to the needed concentration. Typically, a 2 ml liposome suspension was
extruded 14 times to yield a 0.5 ml concentrated formulation.
2.3 Results and Discussions
2.3.1 Synthesis of imidazole-based ether lipids DHI, DHMI and DHDMI. The
synthesis of DHG Tosylate and imidazole-based lipids were carried out to yield three pHsensitive convertible lipids with similar structures. The synthesis methods were based on the
tosyl activation of the lipid DHG and the substitution of the tosylate group with the imidazole
moiety using mercaptoimidazole compounds. Tosylate was known as a reliable leaving group,
so it was used for the conjugation of lipid chains and the imidazole headgroups. The anhydrous
conditions were essential for the high yield of the conjugation reaction. Besides, to purify the
imidazole-based lipids, the mobile phases 1-5% (v/v) methanol/dichloromethane and 3/7 (v/v)
ethyl acetate / hexane were utilized respectively, and the former led to higher yield (30%) than
the latter (10%).
2.3.2 Physicochemical characterization of ICL.
2.3.2.1 Size and PDI before and after DOX-loading. After preparation by lipidic film
hydration, freeze-anneal-thawing and sequential extrusion through 400 nm, 200 nm and 100 nm
polycarbonate membranes, imidazole-based convertible liposomes containing 25% DHI, DHMI
or DHMI were successfully prepared with mean hydrodynamic diameter smaller than 130 nm.
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The Polydispersity Index (PDI), a measure of the heterogeneity of the size of particles in a
mixture, was lower than 0.3 for all the formulations. After the sequential extrusion and before
the loading with DOX, the mean size and PDI of the ICL are shown in Table 2.3 together with
NSL for comparison.

Table 2.3
Size and PDI of empty ICL and NSL after sequential extrusion with 400 nm, 200 nm and 100 nm
polycarbonate membranes and before DOX loading
Ext by 400 nm Ext by 200 nm Ext by 100 nm
Size
Size
Size
Lipid Compositions
Mol Ratio
PDI
PDI
PDI
(nm)
(nm)
(nm)
DHI/DSPC/DPPE-PEG

25/70/5

219.6

0.310

189.1

0.283

124.4

0.195

DHMI/DSPC/DPPE-PEG

25/70/5

179.2

0.149

170.0

0.271

118.7

0.205

DHDMI/DSPC/DPPE-PEG

25/70/5

176.2

0.179

146.5

0.226

105.7

0.178

DSPC/DPPE-PEG

95/5

226.0

0.227

136.9

0.152

104.7

0.050

Note. Size values are the cumulative intensity of hydrodynamic diameters.
After the sequential extrusions, each formulation was passed through a SEC column
(Sephadex G-75) equilibrated with the isotonic HEPES buffer (pH 7.4, 5 mM HEPES, 140 mM
NaCl) to generate the manganese sulfate gradient (300 mM) from inside of liposomes. Such
liposome suspensions were then mixed with DOX in the same buffer at 1000 μg/ml final DOX
concentration in the DOX-liposome mixture. After 90 min incubation at 70˚C and resin removal
of the unencapsulated DOX, the sizes of ICL and NSL significantly increased (Table 2.4). The
DHI/DSPC/DPPE-PEG (last extruded by 100 nm membrane) showed the most increase in the
mean size value from 124.4 nm to 802.7 nm while DHMI/DSPC/DPPE-PEG (last extruded by
100 nm membrane) showed the increase from 118.7 nm to 693 nm. The mean size of the
formulation DHDMI/DSPC/DPPE-PEG increased from 105.7 nm to 404.9 nm after the DOX-
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loading. The non-pH-sensitive control liposome DSPC/DPPE-PEG had similar increase in mean
size from 104.7 nm to 372.7 nm. The liposomes last extruded by the 200 nm polycarbonate
membrane had similar augment in size. The PDI of each formulation also increased after the
drug loading.

Table 2.4
Size and PDI of DOX-loaded ICL and NSL that were last extruded by 200 nm and 100 nm
polycarbonate membranes
Extruded by 200 nm
Extruded by 100 nm
Lipid Compositions

Mol Ratio

Size (nm)

PDI

Size (nm)

PDI

DHI/DSPC/DPPE-PEG

25/70/5

807.6.0

0.845

802.7

0.721

DHMI/DSPC/DPPE-PEG

25/70/5

550.0

0.644

693.0

0.605

DHDMI/DSPC/DPPE-PEG

25/70/5

266.8

0.501

246.1

0.501

DSPC/DPPE-PEG

95/5

401.4

0.246

372.7

0.620

Note. Size values are the cumulative intensity of hydrodynamic diameters.
The pharmacokinetics and tissue distribution of drug delivery systems are remarkably
affected by their size [180]. For PEGylated nano-carriers, it is preferred to keep the size under
200 nm to take advantage of the EPR effect in tumor tissues. In this study, we developed the
methods to prepare drug-free formulations with sizes under 200 nm, but their sizes significantly
increase after being loaded with the payload drug DOX. It was reported that, during drug
loading, DOX induced aggregation of negatively charged liposomes when the temperature is
cooled down to the liposome’s phase transition temperature (Tm) [181]. It was suggested that the
aggregation resulted from the electrostatic interactions between the unencapsulated DOX
molecules (positively charged) and the negatively charged lipids on the liposome surface. It was
also suggested that the DOX molecules that bind to different liposomes may also stack with one

70

another to induce the liposome aggregation. In this study, the aggregation of our ICL and NSL
during drug loading may also result from their electrostatic attraction with DOX. The particle
size of the formulations after drug loading reflected the extent of aggregation. This speculation
is also supported by the ζ- potential measurements of ICL and NSL at pH 6.0-7.4 (Figure 2.4),
which showed that all the three ICL and NSL formulations carried a negative ζ- potential at pH
7.4. The further formulation studies in this chapter aimed to keep the size of the DOX-loaded
formulation under 200 nm by reducing the aggregation while maintaining the pH-sensitivity.
The resultant convertible liposomes would then serve as a viable anticancer drug delivery
system.
2.3.2.2 Encapsulation efficiency (EE)and DOX concentration of ICL. After separating
the DOX-loaded liposomes from unencapsulated DOX in the suspensions, the payload DOX
concentration was measured (Table 2.5) and the EE was calculated from the payload DOX
concentration and the input DOX concentration. The EE of the formulations ranged from 40% to
80%, depending on the lipid compositions.

Table 2.5
Encapsulation efficiency and DOX concentration of ICL and NSL that had been extruded by 200
nm and 100 nm polycarbonate membranes
Extruded by 200 nm
Extruded by 100 nm
Lipid
DOX Conc.
DOX Conc.
Mol Ratio
EE (%)
EE (%)
Compositions
(μg/ml)
(μg/ml)
DHI/DSPC/DP
25/70/5
45.79±0.44
457.92±4.44
41.28±0.45
412.80±4.50
PE-PEG
DHMI/DSPC/
25/70/5
51.64±0.35
516.40±3.51
52.17±1.52 521.68±15.23
DPPE-PEG
DHDMI/DSPC
25/70/5
75.54±1.00 755.44±10.07 65.55±0.65
655. 51±6.50
/DPPE-PEG
DSPC/DPPE95/5
62.35±0.80
623.49±8.02
52.80±0.69
527.96±6.94
PEG
Note. Data presented as mean ± SD, N = 3.
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EE of liposomes is considered a very important characteristic, because higher EE would
allow higher concentration of the payload drug to be delivered to biological systems [177]. The
anticancer activity studies on MCS models needed 250 μg/ml or higher DOX concentration in
the formulations. The results in this study indicated the above formulations were capable of
loading sufficient DOX for the later anticancer activity studies (Chapter V). To achieve a high
loading capacity and efficiency, the manganese sulfate gradient was applied to generate the
transmembrane ion gradient [182], which was acknowledged as one of the well-developed
remote loading methods. At Tm, the membrane of liposomes became more permeable, which
allowed the DOX molecules to diffuse into the liposome aqueous interior, wherein the
concentration of manganese sulfate is much higher than in the extra-liposomal medium.
Manganese formed a complex with DOX, which drove the drug loading and the drug retention in
the liposome aqueous interior.
2.3.2.3 Factors affecting size, PDI and EE. To reduce the sizes of DOX-loaded ICL
while keeping sufficient DOX encapsulation, several methods have been attempted to improve
the formulations. The following sections will discuss a number of formulation conditions that
affect the ICL properties such as size, PDI and EE. Such formulation conditions include drug
loading time, lipid compositions, drug-loading pH, temperature mixing with resin and input
DOX concentration.
2.3.2.3.1 Effect of longer time of drug-loading. To investigate the kinetic changes of size
and EE in drug loading, an aliquot of liposome suspension was taken at different time point of
drug loading (20, 30, 40, 50, 60, 70, 80 and 90 min) to measure its size and EE. As shown in
Figure 2.3 (a), the size of ICL and NSL increased with longer drug-loading time. Compared with
DHDMI/DSPC/DPPE-PEG and NSL, DHI/DSPC/DPPE-PEG and DHMI/DSPC/DPPE-PEG
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showed higher extent of aggregation, where the size increased to 200 nm after 40 min incubation
and 500 nm after 90 min incubation. As shown in Figure 2.3 (b), the EE of ICL and NSL
increased with longer incubation time. The convertible liposomes DHDMI/DSPC/DPPE-PEG
showed the smallest size and the highest EE than the other formulations in this study, which
suggests that the DHDMI/DSPC/DPPE-PEG formulation possesses better stability than the other
formulations.

(b)
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EE (%)

Sizes (nm)
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DHMI/DSPC/DPPE-PEG
DHDMI/DSPC/DPPE-PEG
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DHI/DSPC/DPPE-PEG
DHMI/DSPC/DPPE-PEG
DHDMI/DSPC/DPPE-PEG
DSPC/DPPE-PEG

Figure 2.3. (a) Change of liposome sizes with incubation time in drug loading. Data presented as
mean ± SD, N = 7. (b) Change of EE of liposomes with incubation time in drug loading. Data
presented as mean ± SD, N = 3.
The study obtained the result revealing the correlation between longer incubation time
and larger size of DOX-loaded ICL, which suggested the size of liposomes can be decreased by
shortened incubation time. Nevertheless, based on the result, the aggregation of convertible DHI
and DHMI liposomes started in 40 min, while the EE in 30 min was below 20%. Liposomes
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with EE of 20% contained 200 μg/ml encapsulated DOX, which needed TFF concentrating to
reach the concentration demanded in the cytotoxicity studies on MCS.
2.3.2.3.2 Effect of lipid composition – C18 phospholipid versus C16 phospholipid. To
investigate the influence of phospholipid on DOX-loaded liposomes, liposomes consisting of
70% C16 phospholipid DPPC (DHI/DPPC/DPPE-PEG) were prepared in comparison to
liposomes consisting of 70% C18 phospholipid DSPC (DHI/DSPC/DPPE-PEG). As shown in
Table 2.6, DHI/DPPC/DPPE-PEG liposomes extruded by both 200 nm and 100 nm
polycarbonate membranes showed dramatically larger sizes (over 2000 nm in hydrodynamic
diameter) than the DHI/DSPC/DPPE-PEG liposomes. Interestingly, the larger
DHI/DPPC/DPPE-PEG liposomes carried a smaller PDI than the DHI/DPPC/DPPE-PEG
liposomes, indicating that the DHI/DPPC/DPPE-PEG liposomes are more homogeneous than the
DHI/DSPC/DPPE-PEG liposomes.

Table 2.6
Effect of phospholipid the on the size and PDI of DOX-loaded ICL
Extruded by 200 nm

Extruded by 100 nm

Lipid Compositions

Mol Ratio

Size (nm)

PDI

Size (nm)

PDI

DHI/DSPC/DPPE-PEG

25/70/5

706.3

0.833

429.0

0.788

DHI/DPPC/DPPE-PEG

25/70/5

2355.0

0.354

2126.0

0.343

(Note. Size values are the cumulative intensity of hydrodynamic diameters.
The EE result in Table 2.7 showed that the DHI/DPPC/DPPE-PEG liposomes contained
more payload DOX than the DHI/DSPC/DPPE-PEG liposomes, which demonstrated the higher
extent of aggregation in DPPC-containing ICL didn’t negatively impact the EE. The higher EE
of DHI/DPPC/DPPE-PEG liposomes was consistent with the earlier speculation that the
aggregation result from the liposome-DOX-liposome stacking, which would complex more DOX
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molecules in between the aggregated liposomes. These complexed DOX molecules could not be
removed by the ion-exchange resin, and thus would contribute to the EE.

Table 2.7
Effect of phospholipid on EE and DOX Conc. of ICL
Ext by 200 nm
Lipid
DOX Conc.
Mol Ratio
EE (%)
Compositions
(μg/ml)
DHI/DSPC/DPP
25/70/5
40.99±0.44 409.93±4.36
E-PEG
DHI/DPPC/DPP
25/70/5
72.28±0.98 722.80±9.88
E-PEG
Note. Data presented as mean ± SD, N = 3.

Ext by 100 nm
DOX Conc.
EE (%)
(μg/ml)
46.63±0.73

466.29±7.28

65.22±7.10

652.15±71.00

2.3.2.3.3 Effect of lipid composition - 25% cholesterol. To investigate the influence of
cholesterol, DOX-loaded ICL liposomes containing 25% cholesterol were prepared to compare
with the corresponding cholesterol-free liposomes. As shown in Table 2.8, before DOX loading,
the sizes of liposomes containing cholesterol were below 130 nm after extrusion through the 100
nm polycarbonate membranes, similar to the cholesterol free liposomes in Table 2.8. Based on
the PDI results in Table 2.3 and 2.8, furthermore, the PDI values of ICL with cholesterol (Table
2.8) were all smaller than 0.1 while those of cholesterol-free ICL were all larger than 0.1,
indicating that cholesterol improved the homogeneity of ICL.

Table 2.8
Size and PDI of liposomes consisting of 25% cholesterol after sequential extrusion through 400
nm, 200 nm and 100 nm polycarbonate membranes and before DOX loading
Ext by 400 nm Ext by 200 nm Ext by 100 nm
Size
Size
Size
Lipid Compositions
Mol Ratio
PDI
PDI
PDI
(nm)
(nm)
(nm)
DHI/DSPC/DPPE-PEG/Chol

25/45/5/25

271.1

0.212

164.0

0.197

124.1

0.088

DHMI/DSPC/DPPEPEG/Chol

25/45/5/25

233.6

0.119

145.4

0.145

114.5

0.041
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(Table 2.8 Continued)
DHDMI/DSPC/DPPEPEG/Chol

25/45/5/25

247.0

0.125

159.6

0.181

115.7

0.066

70/5/25

217.3

0.124

172.6

0.212

120.3

0.108

DSPC/DPPE-PEG/Chol

Note. Size values are the cumulative intensity of hydrodynamic diameters
As shown in Table 2.9, after 90 min DOX loading, the sizes and PDI of ICL with
cholesterol didn’t have obvious change. The DOX-loaded cholesterol liposomes had sizes
smaller than 150 nm and PDI below 0.3, which means no significant aggregation took place
during the drug loading, while the EE of all the ICL liposomes with cholesterol reached above
60%.

Table 2.9
Size, PDI and EE of ICL liposomes containing 25% cholesterol after extrusion by 100 nm
polycarbonate membrane and DOX-loading
Lipid Compositions

Mol Ratio

Size (nm)

PDI

EE (%)

DHI/DSPC/DPPE-PEG/Chol

25/45/5/25

133.6

0.145

71.38±0.61

DHMI/DSPC/DPPE-PEG/Chol

25/45/5/25

120.0

0.075

89.86±1.27

DHDMI/DSPC/DPPE-PEG/Chol

25/45/5/25

120.7

0.115

92.97±1.10

DSPC/DPPE-PEG/Chol

70/5/25

144.1

0.266

60.98±1.66

Note. Size values are the cumulative intensity of hydrodynamic diameters. EE data presented as
mean ± SD, N = 3.
Compared with DOX-loaded cholesterol free ICL and NSL, the DOX-loaded ICL and
NSL containing 25% cholesterol showed significantly smaller sizes and higher EE. Thus, the
aggregation during DOX-loading was averted by the introduction of cholesterol.
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Figure 2.4. Effect of cholesterol on sizes and EE of ICL and SNL. (a) Sizes of liposomes with and
without 25% cholesterol. Data presented as mean ± SD, N = 7. *** p < 0.001. (b) EE of liposomes
with and without 25% cholesterol. Data presented as mean ± SD, N = 3. ** p < 0.01, *** p < 0.001.
It was reported that incorporation of cholesterol into the lipid bilayer structure can
improve the stability of liposomal formulations [183, 184]. At T > Tm, the lipid bilayer was in
fluid phase, in which the lipid molecules were restrained to the surface of membranes but
nonetheless free to diffuse within this surface. Each lipid molecule had the process of random
walk to exchange locations with its neighboring lipid molecules. Due to its unique
physicochemical characteristics, cholesterol helps the lipid bilayers exert their thermodynamic
properties. The hydrophilic domain of cholesterol molecule is little (a single hydroxyl group),
which makes it barely resemble phospholipids. The addition of cholesterol was found to help
control the mobility of lipid bilayers in fluid phase and to reduce their permeability to water
[185, 186]. Cholesterol was found to reduce the fluidity of lipid bilayers and to increase their
mechanical rigidity by intercalating between phospholipids and filling in the cavities to decrease
the flexibility of hydrocarbon chains of the surrounding phospholipids [187]. Furthermore, the
inhibition of lipid mobility also reduced the lateral diffusion coefficient of lipid bilayers in fluid
phase. Consequently, the introduction of cholesterol helped stabilize the phospholipid bilayer
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structures when the temperature was elevated above Tm. Conversely, the addition of cholesterol
was also found to interfere with phospholipid bilayers in gel phase by disrupting the local
packing order of their lattice structures. This interaction increased the diffusion coefficient and
decreased the elastic modulus of lipid bilayers in the gel phase [188].
In this study, liposomes were incubated with DOX at 70˚C (T > Tm) for 90 min, and a
protective effect of cholesterol against aggregation was observed while the temperature cooled
down. The above-mentioned studies on cholesterol suggest that on the one hand, cholesterol
would stabilize the fluid state of the liposome bilayers, which would increase the drug retention
of liposomes during drug-loading, while one the other hand, cholesterol would mobilize the
lipids in the bilayers at the gel state bilayers to hinder the aggregation from liposome-DOXliposome stacking. The addition of cholesterol remarkably improved the size and EE.
Therefore, ICL containing no cholesterol and 25% cholesterol were subjected to further studies
to test their pH-sensitivity, stability and anticancer activity in vitro.
2.3.2.3.4 Effect of pH during drug loading. To explore the effect of drug loading pH on
size and EE of DOX-loaded liposomes, liposomes with or without 25% cholesterol were
prepared and loaded with DOX at pH 7.4 or 8.0. As shown in Table 2.10, for both
DHI/DSPC/DPPE-PEG and DSPC/DPPE-PEG, the sizes after DOX loading at pH 8.0 were
dramatically larger than pH 7.4, together with smaller PDI and higher EE. This implies that
loading DOX at pH 8.0 induced higher percentage of aggregated liposomes than at pH 7.4,
similar as the higher extent of aggregation observed in ICL and NSL consisting of DPPC (Table
2.6 and 2.7). For the liposomes consisting of 25% cholesterol, DOX loading at pH 8.0 also
yielded larger liposomes than pH 7.4 but the size increase is not as large as liposomes without
cholesterol.
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Table 2.10
Effect by loading pH. Size, PDI and EE of liposomes loading DOX at pH 7.4 and 8.0
Size
Lipid Compositions
Mol Ratio Loading pH
PDI
EE (%)
(nm)
DHI/DSPC/DPPE-PEG

25/70/5

7.4

808.3

0.857

40.56±4.54

DHI/DSPC/DPPE-PEG

25/70/5

8.0

3260.0

0.643

65.97±1.15

DSPC/DPPE-PEG

95/5

7.4

304.2

1.000

36.69±0.53

DSPC/DPPE-PEG

95/5

8.0

1842.0

0.448

65.61±1.00

DHI/DSPC/DPPE-PEG/Chol

25/45/5/25

7.4

159.9

0.105

91.27±1.97

DHI/DSPC/DPPE-PEG/Chol

25/45/5/25

8.0

208.0

0.278

84.48±2.31

DSPC/DPPE-PEG/Chol

70/5/25

7.4

148.4

0.293

52.95±0.95

DSPC/DPPE-PEG/Chol

70/5/25

8.0

361.0

0.592

69.76±1.58

Note. Size values are the cumulative intensity of hydrodynamic diameters. EE data presented as
mean ± SD, N = 3.
Based on this result, DOX-loading pH considerably affects the sizes of ICL liposomes.
The addition of cholesterol restrained the interaction between liposomes and DOX at both pH 7.4
and 8.0. For the liposomes with cholesterol loading at pH 8.0, the slightly increase of sizes was
the composite outcome of aggregation intensified by the elevated pH and protection effort by
cholesterol.
2.3.2.3.5 Effect of the temperature for mixing with resin to remove unencapsulated DOX.
It was reported that under certain conditions, liposomes can aggregate in the gel phase but not in
fluid phase [181]. In our studies, the ICL aggregated during the cooling down process after
incubation with DOX at T > Tm. To confirm this, size of NSL was measured at 70˚C
immediately after 90 min incubation with DOX at 70˚C before cooling down and compared with
the size of NSL measured at room temperature after cooling down. As shown in Table 2.11, the
cumulative hydrodynamic diameter of NSL before cooling down stayed below 250 nm, which is
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smaller than the cooled downed NSL. The detailed dynamic light scattering result of the size of
NSL after cooling showed a peak of above 1000 nm size, which confirmed aggregation. In
comparison, NSL before cooling down, only showed peaks of sizes similar to or smaller than the
cumulative size. These data confirmed that NSL aggregated when the liposomes were cooled
down and turned into gel phase.

Table 2.11
Cumulative size and intensity of each peak of DOX-loaded liposomes measured at 70˚C
immediately after DOX loading, and at room temperature after suspension cool-down
Lipid
Mol
Measurement Cumulative
Peak 1
Peak 2
PDI
Compositions
Ratio
T (˚C)
Size (nm)
(nm)
(nm)
DSPC/DPPE-PEG

95/5

70

241.1

0.361

234.3

60.23

DSPC/DPPE-PEG

95/5

RT

486.5

1.000

1465.0

121.0

Note. Cumulative size values are the cumulative intensity of hydrodynamic diameters.
Based on the above observation, the DOX-loaded liposomes was mixed with resin at T >
Tm to remove unencapsulated DOX from liposome before the liposomes were cooled down to
form the gel phase in an effort to reduce the aggregation. As shown in Table 2.12, the liposomes
that were mixed with resin at 50˚C had similar average size as those that were mixed with resin
at room temperature, while the liposomes mixed with resin at 60˚C and 70˚C had slightly smaller
average size than at room temperature. The peak 1 (largest peak) of the size measurement of the
liposome mixed with resin at 60˚C and 70˚C showed more evident decrease in the diameter from
that at room temperature compared with liposomes after drug-loading at 50˚C. The EE of
liposomes after being mixed with resin at 60˚C and 70˚C were lower than at room temperature
and 50˚C, which was probably caused by less stacking of DOX on liposomes in fluid phase at
higher temperature.
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Because the percentage of aggregated liposome was reduced after mixing the liposomes
with resin at T ≥ Tm, filtration was attempted to remove the large liposome-DOX aggregates to
further reduce the formulation size. The liposome suspensions were filtered with nylon syringe
filters of 400 nm pore. As shown in Table 2.12, the cumulative size of liposomes after mixing
with resin at different temperature and filtration were decreased below 150 nm. The PDI also
decreased considerably, which indicated the aggregated liposomes were removed. However, the
filtration significantly decreased the EE and the filtered liposomes suspension became more
transparent, indicating that a substantial portion of the liposomes were trapped in the syringe
filters. EE for the liposomes that were mixed with resin at 60˚C or 70˚C followed by filtration
were higher than those that were mixed with resin at 50˚C or room temperature, which is in line
with the results that their extent of aggregation is lower (Table 2.12).

Table 2.12
Size and EE of DOX-loaded liposomes after being mixed with resin at room temperature, 50˚C,
60˚C or 70˚C and the effect of filtration on the size and EE
CompositiMol Mixing Filt- Cumulative
Peak 1 Peak 2
PDI
EE (%)
on
Ratio T (˚C) ered
Size (nm)
(nm)
(nm)
DSPC/DPP
E-PEG

95/5

RT

DSPC/DPP
E-PEG

95/5

50

DSPC/DPP
E-PEG

95/5

60

DSPC/DPP
E-PEG

95/5

70

DHI/DSPC/
DPPE-PEG

25/70
/5

RT

×

486.5

1.000

1465.0

121.0

53.01±0.47

√

208.2

0.184

260.0

44.91

4.61±0.84

×

493.5

0.605

1240.0

118.1

48.23±0.47

√

118.2

0.172

136.1

-

5.99±0.34

×

348.8

0.647

680.6

135.4

28.47±0.60

√

144.7

0.191

184.2

40.7

10.92±0.16

×

428.1

0.684

639.0

118.1

31.17±0.30

√

116.5

0.184

141.8

-

7.58±0.18

×

455.4

0.661

1152.0

139.5

44.36±1.23

√

116.7

0.321

170.8

4233

5.48±1.37

81

(Table 2.12 Continued)
DHI/DSPC/
DPPE-PEG

25/70
/5

70

×

427.0

0.719

724.0

76.08

46.43±0.66

√

125.6

0.370

95.66

256.9

5.01±0.05

Note. Cumulative size values are the cumulative intensity of hydrodynamic diameters. EE data
presented as mean ± SD, N = 3.
The above results indicated mixing liposomes with resin at T ≥ Tm moderated the
aggregating of liposomes but did not sufficiently decrease the average sizes of the formulations.
The Dowex 50WX-4 was known as a cationic ion-exchange resin which bounds with the
unencapsulated DOX and yet leave the DOX molecules that are entrapped by liposome [179].
The result that resin partially diminished the aggregation was in line with the finding that the
stacking of DOX and their binding with liposomes can cause aggregation. In this study, the resin
appeared to have limited capability in removing DOX that were stacked on the surface of
liposomes. Adding resin into the liposome suspension at Tm or even higher temperature only
moderated the aggregation but did not totally prevent it.
The filtration method was commonly used to sterilize liposomal formulations in
industrial manufacturing [189, 190]. Our study indicate that the filtration method can cause
considerable loss of the liposomes when the sample contains liposome aggregates of too large
size (diameter larger than 500 nm).
2.3.2.3.6 Effect of input DOX concentration. To study the effect of input DOX
concentration on size and EE of liposomes, liposomes were mixed with 1000, 500, 250 μg/ml
DOX solutions and incubated for 90 min of drug loading. As can be seen in Figure 2.5 (a), the
sizes of liposomes decreased after incubation with lower and lower DOX concentration, which
was consistent with the prior report that the aggregation resulted from stacking of DOX and their
association with liposomes. As shown in Figure 2.5 (b), the EE remained at the same level in
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liposomes that were incubated with different concentrations of input DOX. Because the input
DOX concentration was reduced, the encapsulated DOX concentration was further considered as
a characteristic of the drug loading, in consideration that the minimum concentration of the DOX
concentration for anticancer studies in MCS models. Although the lower input DOX decreased
the liposome size, the encapsulated DOX concentration of the resultant DHI and NSL liposomes
also dropped below 200 μg/ml, which is required for MCS studies. Therefore, the resultant
formulations were concentrated with a diafiltration column. After extrusion through the
diafiltration column for 14 times, the volume of each liposome suspension was reduced from 2
mL to 0.5 mL while the encapsulated DOX concentration was raised above 300 μg/ml for further
anticancer investigations in MCS.

(b)

(a)
***

100

***
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Figure 2.5. Effect of input DOX concentration on sizes and EE of ICL and SNL. (a) Sizes of
liposomes after DOX loading at different input concentrations. Data presented as mean ± SD, N =
7. *** p < 0.001. (b) EE and encapsulated DOX concentration of liposomes after DOX loading at
different input concentrations. Data presented as mean ± SD, N = 3. ** p < 0.01, *** p < 0.001.
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Based on the results in Table 2.4 and Figure 2.3 (a), the ICL consisting of DHI was more
prone to aggregation during drug loading than ICL consisting of DHMI or DHDMI. Drug
loading at a lower DOX concentration of 200 μg/ml yielded smaller ICL consisting of DHI
(198.8 nm in diameter) and NSL (121.2 nm in diameter), indicating that the input DOX
concentration during drug loading was a significant factor to influence the sizes of DOX-loaded
ICL and NSL. With such method, ICL formulations containing DHI, DHMI and DHDMI were
prepared and characterized with sizes around or below 200 nm (Table 2.13). TFF concentrating
was needed for those formulations before applied in MCS treatment.

Table 2.13
Size, PDI and EE of ICL liposomes lasted extruded by 100 nm polycarbonate membrane and
loaded with 200 μg/ml DOX for 90min.
Lipid Compositions

Mol Ratio

Size (nm)

PDI

EE (%)

DHI/DSPC/DPPE-PEG

25/70/5

198.8

0.531

56.62±2.06

DHMI/DSPC/DPPE-PEG

25/70/5

179.6

0.573

53.18±1.12

DHDMI/DSPC/DPPE-PEG

25/70/5

202.9

0.115

59.54±0.59

DSPC/DPPE-PEG

95/5

121.2

0.266

57.74±0.98

Note. Size values are the cumulative intensity of hydrodynamic diameters. EE data presented as
mean ± SD, N = 3.
2.4 Summary
The imidazole-based ether lipids DHI, DHMI and DHDMI were successfully
synthesized. Using film hydration, freeze-anneal-thawing and extrusion methods, ICL were
successfully prepared with sizes smaller than 130 nm and PDI under 0.3. With manganese
sulfate gradient method at the input DOX concentration of 1000 μg/ml, ICL were loaded with
DOX at EE of at least 40%. The sizes and PDI of DOX-loaded ICL significantly increased
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during DOX-loading due to aggregation. Factors influencing the sizes and EE of ICL were
studied to improve the ICL formulations, including drug loading time, length of acyl chains of
phospholipids, addition of cholesterol, drug-loading pH, temperature of mixing with the resin
and input DOX concentration. Reducing drug loading time, adding cholesterol, mixing with
resin at T ≥ Tm followed with filtration and reducing the input DOX concentration decreased the
sizes of DOX-loaded ICL by inhibiting or preventing the liposome aggregation. Among these
methods, adding 25% cholesterol and reducing the input DOX concentration from 1000 μg/ml
into 200 μg/ml most effectively decreased the sizes of DOX-loaded ICL to about 200 nm in
diameter without dramatically reducing EE. The advantages and disadvantages of these
improvement methods are summarized in Table 2.13.

Table 2.14
Comparison of methods to improve the size and EE of DOX-loaded ICL
Methods

Pros

Cons

Reducing drug loading time

Size ~200 nm

Lowered EE

Incorporation with cholesterol

Size ~140 nm, EE ~70%

Mixing with resin at T ≥ Tm
and filtration

Size ~120 nm

Lowered EE

Reducing input DOX Conc.

Size ~200 nm

Lowered DOX Conc.

The addition of cholesterol seems to be the most effective method to improve the size and
EE. However, modified composition of ICL formulations could also impact their pH-sensitivity.
Thus, pH-sensitivity studies were carried out on both the cholesterol-free ICL and the ICL
containing cholesterol in the next chapter.
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CHAPTER 3: TESTING OF PH-SENSITIVITY OF IMIDAZOLE-BASED CONVERTIBLE
LIPOSOMES

3.1 Introduction
A pH-sensitive liposome is a modified form of liposomes that shows high stability at
physiological pH (pH 7.4) while undergoing destabilization or physicochemical changes under
acidic conditions [23]. pH-sensitive liposomes can serve as viable drug delivery systems
because many physiological and pathological scenarios involve acidic pH, including
endosomal/lysosomal vesicles solid tumors and sites of inflammation [23, 114]. The
composition of the imidazole-based convertible liposomes was designed to protonate in response
to the acidic extracellular pH in tumor (pH 6.0-7.0). The protonated imidazole lipids would then
interact with the negatively charged DPPE-PEG on the liposome membrane to condense them
laterally and thus to unveil the excessive positive charges on the surface of ICL. Such pHtriggered ICL would in turn have stronger electrostatic interaction with cancer cells and/or
release more of the payload drug.
Based on the results of Chapter II, two methods were discovered to considerably improve
the physicochemical properties of ICL: reduction of input DOX concentration during drug
loading and addition of cholesterol in lipid composition. Studies in this chapter aim to test the
pH-sensitivity of ICL by exposing them to aqueous solutions of pH 6.0-7.4 in vitro. Based on
the aforementioned properties of ICL, the pH-sensitivity studies include pH-dependent change of
liposome surface charge (-potential) and pH-dependent DOX release, which would test ICL’s
potential to interact more with negatively charged cells and to release more payload drug at
lower pH, respectively.
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3.1.1 Calculated pKa of the imidazole-based ether lipids. The pKa of the imidazolebased ether lipids DHI, DHMI and DHDMI were calculated using ACD/pKa DB software
(Advanced Chemistry Development, Inc., Ontario, Canada) [191]. Calculation by software was
chosen instead of experimental methods for pKa determination of imidazole-based lipids due to
the assembly of these lipids in aqueous solutions, which makes it hard to trace the protonation
status of each lipid molecule in water. The calculated pKa values of the imidazole-based lipids
are evaluated together with the ζ- potentials measurements of ICL liposomes containing these
lipids to assess the protonation of these lipids in response to different pH. As shown in Table 3.1,
the estimated pKa of the imidazole-based lipids ranges from 5.36 to 6.75. As a lipid with a basic
headgroup, each imidazole-based lipid would protonate more in an acidic environment than
neutral pH. Based on their pKa, their extent of protonation would be ranked DHDMI > DHMI >
DHI.

Table 3.1
Calculated pKa of DHI, DHMI and DHDMI using ACD/pKa DB software. [129]
Imidazole Lipids

pKa

DHI

5.53±0.5

DHMI

6.20±0.5

DHDMI

6.75±0.5

3.1.2 Phase separation of ICL in response to acidic pH. Due to the significantly strong
electrostatic interaction between the imidazole-based lipids and DPPE-PEG, phase separation
was observed in the ICL bilayer at acidic pH, which was reported in our prior studies [129]. The
liposome membrane can separate into multiple phases when interaction between its lipid
components are sufficiently strong [192]. The phase separation in lipid bilayers can be
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monitored by differential scanning calorimetry (DSC), a thermoanalytical technique developed in
1962 [193]. DSC measures the heat a sample absorbs to increase its temperature (aka, heat
capacity) as a function of temperature. Therefore, DSC can attest to lipid phase separation by
recording multiple peaks of higher heat capacities that are generated from the gel-to-liquid
transition of the separated lipid phases at different temperatures (Figure 3.1). The DSC
thermogram of the convertible liposome DHI/DSPC/DPPE-PEG (Figure 3.2) in prior studies of
our group showed a single broad peak at pH 7.4 between 56˚C and 65˚C, which indicated the
gel-to-liquid transition of only one phase and therefore the homogeneous mixing of the lipid
components of ICL (DSPC (C18), DPPE-PEG(C16) and imidazole-based lipids (C16)) at pH 7.4.
At pH 6.0, the DSC thermogram showed an additional broad peak at around 52 ˚C (Figure 3.1),
which indicated the formation of at least two lipid phases on the liposome membrane. The new
lipid phase was probably rich in DSPC because liposomes of only DSPC has a very similar gelto-liquid phase transition temperature of 54˚C. The newly formed lipid phase on the liposomes
supports our proposed mechanism of the pH-sensitivity, where interaction between the
protonated imidazole-based lipids and the negatively charged DPPE-PEG would expulsed the
DSPC to form two phases, one rich in DSPC, and the other in DPPE-PEG.
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(Figure 3.1 Continued)
Figure 3.1. DSC Thermogram of DSPC. [194]
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Figure 3.2. DSC Thermogram of Convertible Liposome I (DHI/DSPC/DPPE-PEG) at pH 7.4 and
6.0. [129]
The acidic pH-triggered phase separation of DOX-loaded ICL would enhance the
anticancer activity in bio-systems. Firstly, the clustering of negatively charged PEGylated lipids
expulsed DSPC doped with positively charged imidazole lipids to form a domain displaying
positive charges. This domain would not only have excess positive charges, but also would be
cleared from steric hindrance of PEG, both of which would strengthen its electrostatic interaction
with negatively charged cell surface. Furthermore, the fractures of the liposome membrane
between the DPPE-PEG-rich phase and the DSPC-rich phase would be more permeable to
diffusion, which would enhance drug release at acidic pH.
3.2 Materials and Methods
3.2.1 Materials. 2-[4-(2-hydroxyethyl)piperazin-1-yl]-ethanesulfonic acid (HEPES) and
2-(N-morpholino)ethanesulfonic acid (MES) were purchased from Fisher Scientific (Hampton,
NH, US). The lipids 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-
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snglycero-3-phosphoethanolamine-N-[azido(polyethylene glycol)-2000 (DPPE-PEG (2000)), 1palmitoyl-2-oleoyl-glycero-3 phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3phosphoethanolamine (POPE), 1-palmitoyl-2-oleoyl-sn-glycero-3 phospho-L-serine (sodium
salt) (POPS) and L-α-phosphatidylinositol (Soy) (L-R-PI) were purchased from Avanti Polar
Lipids, Inc. (Alabaster, AL, USA). Cholesterol, Dowex® 50WX-4 (50-100 mesh), Sephadex G25 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Doxorubicin Hydrochloride was
purchased from Biotang (Waltham, MA, USA). All other organic solvents and chemicals were
purchased from Sigma Aldrich, Fisher Scientific or VWR.
3.2.2 pH-triggered acquisition of positive charges by ICL. The ζ- potential of ICL and
the mean sizes of ICL mixed with equimolar model liposomes at pH 6.0, 6.5, 7.0 7.4 were
measured to monitor the pH-triggered acquisition of positive charges by ICL.
3.2.2.1 ζ- potential measurement at pH 6.0, 6.5, 7.0, 7.4. In order to enhance the
detection of changes in liposome surface charge, ICL and NSL were prepared by hydration in an
isotone buffer of low ionic strength (pH 7.4, 5 mM HEPES, 5% (w/v) Glucose) [195]. The
liposome preparation methods were similar as in 2.2.2.1. An aliquot (50-100 μL) of the resultant
suspension of ICL or NSL was diluted in 900 μL isotonic MES buffer (pH 6.0 and 6.5, 10 mM
MES, 5% (w/v) Glucose) and isotonic HEPES buffer (pH 7.0 and 7.4, 10 mM HEPES, 5% (w/v)
Glucose), and the ζ- potentials was measured at 37˚C based on electrophoresis mobility under
applied voltage (Zetasizer ZS90, Malvern Instruments Ltd., UK).
3.2.2.2 Interaction of ICL with model liposomes. The model liposomes [196, 197]
mimicking the lipid composition of biomembranes were prepared using film hydration, freezethawing and extrusion. Briefly, a chloroform solution of POPC: POPE: POPS: L-R-PI:
cholesterol = 50:20:5:10:15 (mol%) in a recovery flask was evaporated under reduced pressure
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to form a lipidic film on a Buchi rotavapor at room temperature. The lipidic film was further
dried in vacuum oven for over 4 hours at room temperature to remove the residual of solvent
completely. The lipidic film was then hydrated with isotonic HEPES buffer (pH 7.4, 5 mM
HEPES, 140 mM NaCl) by intermittent agitation to obtain a liposomes suspension containing 20
mM total lipids. The flask was filled with argon and sealed with parafilm. The Liposome
suspension was freeze-thawed by rapidly freezing in liquid nitrogen, emerging in ice-water
mixture for 2 min and thawing in water at room temperature for 5 min. The freeze-annealthawing was repeated for 11 times. The liposome suspension was extruded 11 times though 400
nm polycarbonate membranes (Nucleopore Corp., Pleasanton, CA, US) at room temperature
using a handling Mini-extruder (Avanti Polar Lipids Inc., Alabaster, AL). The mean size of the
resultant model liposomes was 192.7 nm in diameter as measured by Zetasizer ZS90. Liposome
suspension of ICL and NSL were mixed with the model liposome containing equimolar total
lipid and 5 μL of the mixture was diluted in 150 μL isotonic MES buffer (pH 6.0 and 6.5, 10 mM
MES, 140 mM NaCl) and isotonic HEPES buffer (pH 7.0 and 7.4, 10 mM HEPES, 140 mM
NaCl). The size of the particles in the diluted mixtures was measured at 37˚C by dynamic light
scattering (Zetasizer ZS90, Malvern Instruments Ltd., UK).
3.2.3 pH-triggered drug release of ICL.
3.2.3.1 Qualification of initial DOX Concentration in liposomes diluted with buffers at
pH 6.0, 6.5, 7.0, 7.4. Liposome formulation (100 L) was severally diluted with 500 μL MES
buffer (pH 6.0 and 6.5, 100 mM MES, 1.7% (w/v) Glucose) and HEPES buffer (pH 7.0 and 7.4,
100 mM HEPES, 1.7% (w/v) Glucose) in 1.5 mL Amber glass vials. An aliquot (10 μL) of each
diluted sample was immediately lysed with 90 μL lysing buffer (90% (v/v) isopropanol, 0.075 M
HCl) in a 96-well Black Clear Bottom Polystyrene microplate (Corning®, NY, US) and the
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initial DOX concentration Ci (as at time point 0 hour) was qualified with a standard calibration
curve generated from the standard DOX solutions as mentioned in 2.2.4. All samples in 96-well
microplate were triplicated. The microplates with samples were covered with foil before reading.
3.2.3.2 pH-triggered drug release from liposomes determined by direct resin
adsorption. The liposome samples diluted by buffer at different pH (6.0, 6.5, 7.0, 7.4) as in
2.2.5.1 were mixed with cation-exchange resin Dowex® 50WX-4 (50-100 mesh) at DOX: resin
= 1:200 (w/w) ratio. The mixtures were incubated and gently shaken in an incubator at 37˚C. An
aliquot (10 μL) of supernatant was taken from each sample at time points 1, 3, 6, 12, 24, 48
hours to be lysed with 90 μL lysing buffer (90% (v/v) isopropanol, 0.075 M HCl) in a 96-well
Black Clear Bottom Polystyrene microplate(Corning®, NY, US). The DOX concentration of
supernatant Cs, which is the concentration of DOX retained in liposome was qualified by
fluorescent spectrometry using a standard calibration curve generated from the standard DOX
solutions as mentioned in 2.2.4. All samples in 96-well microplate were triplicated. The
microplates with samples before recording were covered with foil. The percentage of released
DOX was determined by the following equation,
% 𝑅𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝐷𝑂𝑋 = (1 −

𝐶𝑠
) × 100%
𝐶𝑖

Where Cs = concentration of DOX retained in liposome after resin absorption, Ci = initial
liposomal DOX concentration.
3.3 Results and Discussions
3.3.1 pH-triggered acquisition of positive charges by ICL.
3.3.1.1 Acidic pH-triggered elevation of ζ- potentials of ICL. ζ- potentials of drug-free
ICL and NSL at pH 6.0, 6.5, 7.0, and 7.4, at 37˚C were measured to evaluate the pH-sensitivity
of ICL. As shown in Figure 3.3 (a), all three of the cholesterol-free ICL (DHI, DHMI and
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DHDMI) showed significant increase of ζ- potential when pH was adjusted from 7.4 to 6.0.
Particularly, the ICL containing DHMI and DHDMI were converted to possess positive surface
charges at pH 6.0. The extent of the ζ- potential increase of ICL was correlated with the pKa of
their imidazole-based lipids (pKa: DHDMI > DHMI > DHI). This result demonstrated that the
pH-sensitivity of ICL was rendered by the protonation of the imidazole-based lipids DHI, DHMI
and DHDMI. By contrast, the NSL (DSPC/DPPE-PEG) displayed negative ζ- potentials below 10 mV at both physiology and acidic pH. However, as can be seen in Figure 3.3 (b), the three
ICL containing 25% cholesterol didn’t show noticeable rise of ζ- potentials at any of the pH
under this study but instead fluctuated between -5 mV and -20 mV. This result indicated that the
pH-sensitivity of ICL, as displayed by the acidic pH-triggered acquisition of positive surface
charges, was prohibited by the addition of 25% cholesterol.
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Figure 3.3. ζ- potential of ICL without (a) or with (b) 25% cholesterol at 37 ℃, pH 6.0, 6.5, 7.0,
and 7.4. Data presented as mean ± SD, N = 3.
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3.3.1.2 Acidic pH-triggered interaction between ICL and model liposome. The acidic
pH-triggered interaction of ICL with model liposomes was characterized based on prior studies
in our group [129]. The negatively charged model liposomes, utilized as a simple and fast model
to simulate the components and electrostatic property of biomembranes, were successfully
prepared as shown in Table 3.2.

Table 3.2
Size, PDI and ζ- potential of model liposomes
Lipid Compositions

Mol Ratio

Size (nm)

PDI

POPC/POPE/POPS/L-R-PI/Chol

50/20/5/10/15

192.7

0.180

ζ- potential

(mV)

-51.77±1.18

The stock preparation of the model liposomes was diluted in isotonic buffer at pH 6.0,
6.5, 7.0 and 7.4, and then mixed with equimolar drug-free ICL and NSL. The particle size of the
mixture was measured at 37℃. As shown in Figure 3.4 (a), the DHDMI/DSPC/DPPE-PEG
showed remarkable increase of the cumulative size at pH 6.0 compared with pH 7.4. The size
increase indicated the aggregation between ICL and model liposomes due to the electrostatic
interaction. By contrast, as shown in Figure 3.4 (b), the mixture of model liposomes and ICL
consisting of cholesterol did not show noticeable size increase, which indicated no aggregation
between ICL containing cholesterol and the model liposomes.
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Figure 3.4. (a) Mean sizes of equimolar mixture of model liposome and DHDMI/DSPC/DPPEPEG at pH 6.0, 6.5, 7.0, and 7.4. Data presented as mean ± SD, N = 3. (b) Mean size of
equimolar mixture of model liposome and liposome containing cholesterol at pH 6.0, 6.5, 7.0,
and 7.4. Data presented as mean ± SD, N = 3.
Based on the results in 3.3.1, the introduction of imidazole-based convertible lipids
introduced pH-sensitivity to liposomes, while the addition of cholesterol was found to suppress
the pH-sensitivity. As directly displayed by the pH-triggered rise of ζ- potentials and further
supported by the pH-triggered interaction with model liposomes, the cholesterol-free ICL were
negatively charged at pH 7.4 and yet converted to cationic liposomes at acidic pH, while the ICL
containing cholesterol showed negative surface charges at both pH 7.4 and acidic pH. As
discussed in 2.3.2.3.3, cholesterol was reported to help stabilize the fluid phase bilayer structures
of liposomes by inserting into cavities between phospholipids to control the flexibility of the
hydrocarbon chains. However, at T < Tm, incorporation of cholesterol obstructed the movements
of phospholipids within the surface of bilayers. An “umbrella model” was proposed to explain
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the multibody interaction between cholesterol and phospholipid headgroups in phospholipid
bilayers containing cholesterol [192, 198]. Even though cholesterol has a high solubility in
phospholipids (about 67 mol % at saturation for many types of PC), the cholesterol molecules are
prone to tie up their neighboring phospholipids to accommodate in a lattice structure that is
stable in water [192]. In a bilayer structure, the nonpolar cholesterols must be covered by polar
phospholipid headgroups to minimize its thermodynamically unfavorable exposure to water at
the membrane-water interface. Such required coverage substantially limits the lateral diffusion
of the lipids compared to the corresponding cholesterol-free bilayers. Furthermore, it was also
demonstrated that as phospholipid headgroups cover cholesterol to form the “umbrella”, the
hydrophobicity of the liposome membrane increases, which further reduces its affinity with
cations [199].
This “umbrella model” is consistent with the results in our studies. The distinct display
of surface positive charges by ICL would need not only protonation of the imidazole-based lipids
but also the phase separation that was implemented by the lateral redistribution and assembly of
negatively charged DPPE-PEG and positively charged imidazole-based lipids. In our study, the
pH-sensitivity was recorded in conditions at 37˚C, which is below the Tm of ICL (estimated
63˚C). Therefore, based on the “umbrella model”, DPPE-PEG and imidazole-based lipids would
not be able to cluster at acidic pH when cholesterol prohibits the lipid lateral redistribution by
tying up the surrounding phospholipids. Furthermore, the addition of cholesterol increases the
hydrophobicity of the liposome membrane, which would reduce its affinity with protons, and
thus reduce the protonation of imidazole-based lipids. Such speculation is supported by the
observation that ICL with cholesterol maintained negative a -potentials at acidic pH. In our
studies, the stabilization effect by the incorporated 25% cholesterol at T ≥ Tm improved the
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physicochemical properties of DOX-loaded ICL. However, the inhibition of the lipid lateral
diffusion by cholesterol at T < Tm also inhibited the pH-triggered display of positive charges by
ICL. Therefore, further drug release and cytotoxicity studies were carried out to evaluate ICL
with and without cholesterol.
3.3.2 pH-triggered drug release of ICL. Drug release studies were carried out to
further test the stability and pH-sensitivity of ICL without or with cholesterol. After extrusion by
200 nm and 100 nm polycarbonate membrane, ICL without or with cholesterol were loaded with
DOX and then incubated at 37˚C, pH 6.0, 6.5, 7.0, and 7.4 for 12 hours, and the change of
fluorescence of DOX was recorded to calculate the drug release. As shown in Figure 3.5, the
DHI, DHMI, DHDMI and NSL liposomes without cholesterol released 62.91±7.15%,
47.15±4.98%, 19.02±3.27% and 24.15±1.28%, respectively, of the encapsulated DOX after
incubation at pH 7.4 for 12 hours, which indicated that the stability of DHDMI and NSL
liposomes were higher than DHI and DHDMI liposomes at the physiological pH 7.4
environment. Figure 3.5 (b) showed the DHMI liposomes released more DOX at pH 6.0 than
other higher pH, which again illustrated that the DHMI formulation was sensitive to the acidic
pH. According to Figure 3.5 (c) and (d), the DHDMI and NSL liposomes showed no evident low
pH-triggered increase in drug release. Figure 3.5 (a) showed the DHI liposomes released more
DOX at pH 6.0 than pH 6.5 and 7.0 but not more than pH 7.4, which might be due to its
relatively low stability at pH 7.4.
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Figure 3.5. The percentage of DOX release from liposomes extruded by 200 nm over 12 hours at
37 ℃, pH 6.0, 6.5, 7.0, 7.4. Data presented as mean ± SD, N = 3.
As shown in Figure 3.6, for cholesterol-free liposomes that had been extruded by 100 nm
polycarbonate membrane, the DHI, DHMI, DHDMI and NSL liposomes incubated released
64.53±1.74%, 53.65±2.27%, 20.36±0.83% and 29.56±0.70% DOX in 12 hours at pH 7.4, which
was in consistence with the formulations extruded by 200 nm. Specifically, Figure 3.6 (b)
showed remarkable enhanced drug release of DHMI liposomes at pH 6.0 compared with higher
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pH. However, Figure 3.6 (a) (c) and (d) showed no obvious acidic pH-triggered enhancement of
drug release from DHI, DHDMI and NSL liposomes.
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Figure 3.6. The percentage of released DOX of liposomes extruded by 100 nm over 12 hours of
incubation at 37 ℃, pH 6.0, 6.5, 7.0, and 7.4. Data presented as mean ± SD, N = 3.
As shown in Figure 3.7, after incorporation of 25% cholesterol and extrusion through 100
nm polycarbonate membrane, the DHI, DHMI, DHDMI and NSL liposomes released
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56.19±0.78%, 47.11±0.60%, 40.32±0.99% and 57.70±3.03% DOX, respectively after incubation
at pH 7.4 for 12 hours. Compared with the cholesterol-free counterparts, the DHI and DHMI
liposomes with cholesterol showed similar level of drug release, while the DHDMI and NSL
liposomes with cholesterol showed increased drug release. None of the formulation with
cholesterol showed pH-triggered enhancement in drug release, which indicates that the addition
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Figure 3.7. Release of DOX from liposomes consisting of 25% cholesterol and extruded by 100
nm over 12 hours of incubation at 37 ℃, pH 6.0, 6.5, 7.0, and 7.4. Data presented as mean ± SD,
N = 3.
In the drug release study, the stability (presented as drug retention at physiology pH 7.4)
and pH-sensitivity of ICL and NSL at 37℃ were characterized, and the effect of cholesterol
incorporation was investigated. In this study, the cholesterol-free ICL containing DHMI showed
pH-triggered increase of drug release, which would favor its anticancer activity in the acidic
tumor microenvironment. The ICL consisting of DHI showed some enhanced drug release
however also released substantial percentage of the drug at pH 7.4, which suggests that DHI ICL
are less stable than DHMI ICL. The drug release of DHDMI and NSL liposomes showed no
sensitivity to acidic pH but better stability than DHI and DHMI liposomes at pH 7.4, 37℃. The
sensitivity to acidic pH in the drug release study could be explained by the phase separation of
ICL at acidic pH, which resulted in destabilization of liposomes. It was reported the release of
content entrapped in liposomes was the consequence of accelerated diffusion through the
liposomal membranes [200]. The release of content would occur when liposomes lose some or
all of their membrane integrity, thus leaking out some or all of the entrapped content to the
external media over time. The stability of liposomes was reported to be correlated with the
length of acyl chains of lipids [177]. The release kinetics can be controlled by the addition of
different lipid components possessing different Tm, because the lateral diffusion coefficient
depends on lipid packing and acyl chain ordering [201]. The liposomes containing
phospholipids with longer acyl chains would have a higher Tm and higher stability. In our study,
at pH 6.0, the liposome membrane would consist of the imidazole-based lipids (C16)/DPPE-PEG
(C16)-rich phase and the DSPC (C18)-rich phase, owing to the electrostatic interaction between

101

positively charged imidazole-based lipids and the negatively charged DPPE-PEG. Based on the
correlation between liposome stability and the length of acyl chains of lipids, the C16-rich phase
in ICL would possess less stability compared to the phase of evenly distributed C16 and C18 at
pH 7.4, therefore the entrapped DOX would leak out faster through the C16 rich phase.
Based on the results of the drug release study, the addition of cholesterol hindered the
sensitivity to acidic pH of ICL but enhanced the drug release of ICL at 37℃. Similar with
cholesterol’s prohibition of pH-triggered display of positive surface charges, the prohibition of
pH-triggered drug release can also be explained by cholesterol’s inhibition of the phase
separation of ICL. According to the “umbrella model” [199] that is explained in 3.3.1, the
cholesterol molecules associate with the neighboring phospholipids because of their poor
polarity, hence hindering the lateral redistribution of the lipids to form separate phases.
Moreover, the addition of cholesterol to lipid bilayers in gel phase was reported to disrupt the
original packing of lipids, thus increasing the lateral diffusion coefficient of the bilayers at T <
Tm [188, 202]. This can explain the enhancement of drug released from ICL with cholesterol
compared with cholesterol-free ICL at pH 7.4.
The physical stability of liposomes concerns the maintenance of liposome size against
aggregation and fusion and the retention of entrapped drug against premature leakage [177].
Therefore, evaluation of ICL stability needs comprehensive assessment of their size,
encapsulation efficiency (EE), and drug release. In our case, EE is determined both by the
efficiency of the drug loading that is driven by ion gradient and by drug leaking out during the
drug loading. Therefore, both size and EE of DOX-loaded liposomes reflects their stability at the
temperature during drug loading (T ≥Tm). On the other hand, drug release of ICL indicates their
stability at 37˚C (T < Tm), at which the drug release is assessed. Among the DOX-loaded
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cholesterol-free liposomes (ICL and NSL) (Table 3.3), the liposome of better stability at T ≥Tm
(smaller sizes and higher EE) also showed more stability at 37˚C (slower drug release in 12
hours at 37˚C). DHDMI/DSPC/DPPE-PEG showed the highest stability among all the
cholesterol-free liposomes. The addition of cholesterol appeared to increase the stability of
liposomes at T ≥ Tm but decrease their stability at 37˚C. This is consistent with the prior findings
that for the bilayers incorporated with cholesterol, their lateral diffusion coefficient is reduced at
T ≥ Tm due to the decrease of lipid mobility [125, 186], but increased at T < Tm due to the
disturbance of lattice arrangement [188]. This effect induced the formulations to leak the
entrapped DOX faster than the cholesterol-free counterparts at 37˚C.

Table 3.3
Comparison of sizes, EE and DOX release (at pH 7.4 in 12 hours) reflecting stability of
liposomes at T ≥Tm and at 37˚C
T ≥Tm
37˚C (T < Tm)
Lipid Mol
DOX Release
Ratio
Lipid Compositions
Sizes (nm)
EE (%)
(%)
DHI/DSPC/DPPE-PEG

25/70/5

802.7

41.28±0.45

64.53±1.74

DHMI/DSPC/DPPE-PEG

25/70/5

693.0

52.17±1.52

53.65±2.27

DHDMI/DSPC/DPPE-PEG

25/70/5

246.1

65.55±0.65

20.36±0.83

DSPC/DPPE-PEG

95/5

372.7

52.80±0.69

29.56±0.70

DHI/DSPC/DPPE-PEG/Chol

25/45/5/25

133.6

71.38±0.61

56.19±0.78

DHMI/DSPC/DPPE-PEG/Chol

25/45/5/25

120.0

89.86±1.27

47.11±0.60

DHDMI/DSPC/DPPE-PEG/Chol

25/45/5/25

120.7

92.97±1.10

40.32±0.99

DSPC/DPPE-PEG/Chol

70/5/25

144.1

60.98±1.66

57.70±3.03

Note. Size values are the cumulative intensity of hydrodynamic diameters. EE and DOX release
data presented as mean ± SD, N = 3.
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3.4 Summary
The pH-dependent ζ- potential measurement assays, model liposome-interaction assays,
and drug release assays were carried out to characterize the pH-sensitivity of ICL with and
without cholesterol. The cholesterol-free ICL formulations containing DHI, DHMI or DHDMI
showed substantial pH-sensitivity by elevation of ζ- potentials and by interaction with model
liposomes, indicating their conversion in response to acidic pH (pH 6.0-7.0). The ICL containing
DHMI also showed low pH-enhanced drug release. However, the incorporation of cholesterol
hindered both the pH-triggered display of positive surface charge and the pH-triggered drug
release of ICL.
Based on the results of Chapter II and Chapter III, it is found that although incorporation
of cholesterol seems to be highly effective in improving the sizes and EE of ICL, it has the
disadvantage of prohibiting the pH-sensitivity. In comparison, reducing the input DOX
concentration during drug-loading appears to be a more practical way to decrease the size of ICL
while maintaining their pH-sensitivity. ICL of smaller size, higher EE and higher pH-sensitivity
would favor the anticancer activity of ICL in biological systems.
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CHAPTER 4: MORPHOLOGICAL STUDIES ON IMIDAZOLE-BASED CONVERTIBLE
LIPOSOMES USING TRANSMISSION ELECTRON MICROSCOPY (TEM)

4.1 Introduction
Transmission electron microscopy (TEM) is a microscopy technique using a beam of
electrons to transmit through a specimen to obtain an image. As the beam transmits through a
specimen, its electrons interact with the sample to form the image. Compared with light
microscopy, TEM is capable of imaging in outstandingly higher resolutions. The smaller de
Broglie wavelength [203] of electrons enables the TEM instrument to capture fine morphological
details, such as structures of nanotubes and virus. Therefore, TEM finds applications in cancer
research, virology, nanotechnology and material science. In conventional TEM, the specimen
must be either cut into ultrathin sections (< 100 nm thick) or suspended and then coated onto a
grid [204] to allow the transmission of the electron beam. Specimen preparation is specific to
the materials to be analyzed and types of information to be obtained from the images. The
samples/sample areas with heavy metals would appear darker and have greater contrast against
the background while the samples consisting of non-metals would not scatter electrons and thus
cannot be distinguished from the background. Hence, such non-metal samples need to be stained
with a heavy metal stain during specimen preparation [205]. The stain absorbs the passing
electrons which would otherwise be projected onto the imaging detector. Solutions/suspensions
of salts of heavy metals such as osmium, lead, uranium and gold can be used as the stain of TEM
imaging (7). TEM samples can be stained with either positive stains that bind to the actual
specimen and visualize the internal components or negative stains that bind to the background
and visualize the size and shape of the specimen [206].
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In this chapter’s studies, we aimed to utilize TEM techniques to record the morphology of
ICL at physiological pH 7.4 and acidic pH. Comparison of the images at different pHs will test
and monitor ICL’s morphological changes in response to acidic pH.
4.1.1 Negative staining techniques in TEM. Negative staining is a technique applied in
microscopy to contrast a specimen against the background, in which the background is stained,
and the actual specimen is excluded from the staining. In the case of TEM, opaqueness to
electrons is affected by number of protons in the nuclei of the sample. Commonly used negative
stains include ammonium molybdate, uranyl acetate (UA), uranyl formate (UF), phosphotungstic
acid (PTA), osmium tetroxide and osmium ferricyanide [15], owing to their capability to scatter
electrons and adsorption to biological matter. Negative staining technique has been applied to
image virus, bacteria, biological membrane structures and protein, due to their low capacity to
scatter electrons [207]. Beside biological samples, negative staining has also been employed to
study lipidic colloids in aqueous media, such as lamellar liposomes and inverted micelles [208].
Negative staining was reported to lead to flattening of specimen [209, 210]. As shown in Figure
4.1, a liposome which possesses spherical structure would be flattened but still intact in negative
stain.

Liposome in solution

Flattened intact liposome in negative stain

Figure 4.1. Schematic of liposome in solution and flattened intact liposome in negative stain under
TEM. [211]
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4.1.2 Application of TEM in characterization of nanomedicines. The development of
microscopic techniques has made the studies on the surface and inner structure of nanocarriers
more straightforward and attractive [212]. A collection of imaging techniques is available to
characterize the morphology of liposomes and other nanoparticles, including atomic force
microscopy, environmental scanning electron microscopy (ESEM), transmission electron
microscopy (TEM) and confocal laser scanning microscopy. Evaluation of the morphology of
nanomedicine is crucial for the development of nanomedicines because in vivo behavior of
nanomedicines is heavily affected by their physical characteristics, including size, homogeneity,
surface characteristics and lamellarity [211]. Because of its capacity to visualize single particles
and even provide information on their inner structure, TEM represents an important method to
characterize nanoparticles. Three types of TEM methods – drying, staining and cryogenic TEM
(cryo-TEM) are commonly used to image nanostructures. Unlike metal particles which can be
imaged directly due to their high density and stable structures, nanoparticles composed of soft
materials need preservation prior to TEM [213]. Cryo-TEM is so far considered the best method
to visualize the native structure of liposomes, in which an ultrathin film of specimen is quickly
frozen in liquid ethane or a mixture of liquid ethane and propane to generate vitrified films to be
imaged under TEM at cryogenic temperatures [214]. Figure 4.2 shows TEM images of DOXNP® (Liposomal Encapsulated Doxorubicin) prepared with drying, negative staining and cryoTEM methods. Because cryo-TEM requires advanced equipment and relatively complicated
procedures, the faster and simpler TEM with negative staining is also a commonly used method
to image liposomes [205].
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Figure 4.2. Dox-NP® imaged by commonly used TEM techniques: dried sample without staining
(a), UA-stained sample after two minutes of drying (b), negative stained sample (UA) (c) and cryoTEM (d). White scale bars represent 200 nm and black scale bars 50 nm. [205]
4.2 Materials and Methods
4.2.1 Materials. Carbon-coated copper grids (200 mesh) were purchased from
Polysciences (US). Filter paper was purchased from Fisher Scientific (Hampton, NH, US).
Uranyl acetate (UA) was purchased from Sigma-Aldrich (St Louis, MO, US). 2-[4-(2hydroxyethyl)piperazin-1-yl]-ethanesulfonic acid (HEPES) and 2-(N-morpholino)ethanesulfonic
acid (MES) were purchased from Fisher Scientific (Hampton, NH, US).
4.2.2 Preparation of ICL samples for TEM characterization. The morphology of ICL
formulation was observed on a JEOL-JEM 1230 Electron Microscope (JEOL, Japan). Twohundred mesh carbon-coated copper TEM grids were exposed to glow to discharge before use to
increase their hydrophilicity. An aliquot (5 µL) of diluted ICL suspension (approximately 1 mM
total lipids) was dripped onto the grid to wet its surface for 1 min and then blotted with a filter
paper to generate a thin film. The sample film was then wetted five times with 5 µL of the
negative stain (2% uranyl acetate (UA)) between blotting. The grid was dried at room
temperature and then transferred into the electron microscope for imaging at an accelerating
voltage of 100 kV, with the help of Dr. Fei Guo at the Electron Imaging Facility, Department of
Molecular and Cellular Biology, UC Davis.
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4.2.3 Preparation of ICL samples at acidic pH. To characterize the morphological
changes of liposomes in response to acidic pH with TEM, the pH of ICL suspension was
adjusted from 7.4 to 6.0. An aliquot (5 µL) of ICL suspension (approximately 1 mM total lipids) was
dripped onto the grid and blotted with a filter paper. A small volume (5 µL) of isotonic MES
buffer (pH 6.0, 10 mM MES, 140 mM NaCl) was then dripped onto the grid to cover the sample
film for 5 min and then blotted prior to TEM sample staining. The TEM sample staining and
imaging procedures were the same as in 4.2.2.
4.2.4 Preparation of ICL-model liposome mixtures for TEM characterization. To
characterize the interaction between ICL and negatively charged model liposomes under TEM,
ICL formulations were mixed with model liposomes and TEM of the mixture were taken at pH
7.4 and 6.0. An aliquot (5 µL) of ICL suspension (approximately 1 mM total lipids) and 5 µL of
model liposome suspension (approximately 1 mM total lipids) were mixed and 5 µL of the
mixture was dripped onto the grid and then blotted with a filter paper. For TEM of the mixture at
pH 7.4, the sample on the grid was stained by 2% UA directly after the above procedures. For
TEM of the mixture at pH 6.0, 5 µL of isotonic MES buffer (pH 6.0, 10 mM MES, 140 mM
NaCl) was dripped onto the grid to cover the sample film for 5 min and blotted prior to negative
staining. The TEM sample staining and imaging procedures were the same as in 4.2.2.
4.3 Result and Discussions.
4.3.1 Morphology of ICL at pH 7.4. As shown in Figure 4.3 (a-b), the
DHI/DSPC/DPPE-PEG liposome suspension contained spherical and homogeneous particles
with 80-150 nm size. The morphology of DHI liposomes at pH 6.0 (Figure 4.3 (c-d)) appears to
be slightly brighter than at pH 7.4.
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(a)

(b)

(c)

(d)

pH 7.4

pH 6.0

Figure 4.3. TEM images of DOX-loaded DHI/DSPC/DPPE-PEG at pH 7.4 (a-b) and 6.0 (c-d).
As can be seen in Figure 4.4 (a-b), the DHMI/DSPC/DPPE-PEG showed intact and
spherical structures at pH 7.4. At pH 6.0 (Figure 4.4 (c-e)), the liposomes showed much brighter
particles in the TEM images. Some collapsed, non-vesicle structures were also observed.
(a)

pH 7.4

(b)
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(Figure 4.4 Continued)
(c)

(d)

(e)

pH 6.0

Figure 4.4. TEM images of DOX-loaded DHI/DSPC/DPPE-PEG at pH 7.4 (a-b) and 6.0 (c-e).
The darker area displayed in TEM images represent contents that are stained more by
uranyl acetate, while the brighter area represents contents that are stained less with uranyl
acetate. It has been known that the negative staining contrasts the specimen by staining the
background and excluding the specimen, thus the stain should not bind with the specimen
ideally. However, in the UA aqueous solution (pH 4.2-4.9), the uranyl species with positive
charge dominate, thus negatively charged molecules stained particularly well [215]. Uranyl ions
in were reported to bind specifically to phosphate groups in phospholipids, owing to both
electrostatic interaction and chemical reaction [216]. In our results, the DHMI/DSPC/DPPEPEG liposomes were inadequately contrasted at pH 7.4, but became evidently much brighter at
pH 6.0, indicating that less UA stain was binding with the liposomes at pH 6.0, which is
probably because the liposomes converted to cationic liposomes and became exclusive to the
positively charged UA stain. This is in line with the pH-triggered acquisition of positive charges
by ICL confirmed in Chapter III. Similarly, DHI/DSPC/DPPE-PEG at pH 6.0 turned slightly
brighter than at pH 7.4, indicating they probably also acquired some positive charges. In
addition, the images of the DHMI/DSPC/DPPE-PEG at pH 6.0 also showed some deformed and
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scattered structures (Figure 4.4 (c) and (d)). These fragmented structures are probably the
remains of liposomes that had burst and released drug in respond of acidic pH.
As shown in Figure 4.5 (a-b), the morphology of DHDMI/DSPC/DPPE-PEG appeared to
have smaller average size compared with the corresponding DHI/DSPC/DPPE-PEG and DHMI
/DSPC/DPPE-PEG liposomes. Some DHDMI/DSPC/DPPE-PEG liposomes showed two
differently stained areas on the surface (Figure 4.5 (b)), which is probably due to the phase
separation caused by interaction between DHDMI and DPPE-PEG. Figure 4.5 (c-e) showed
evident change of morphology of DHDMI/DSPC/DPPE-PEG liposomes in that the liposomes
were partially turned much brighter showed extremely sharper and clearer boundary of two
differently stained phases at pH 6.0 compared with pH 7.4.

a.

b.

c.

d.

pH 7.4

pH 6.0

e.
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(Figure 4.5 Continued)
Figure 4.5. TEM images of DOX-loaded DHDMI/DSPC/DPPE-PEG at pH 7.4 (a-b) and 6.0 (ce).
Similar to DHMI/PSPC/DPPE-PEG liposomes, the response of DHDMI/DSPC/DPPEPEG liposomes to acidic pH as shown by the TEM images can also be explained by the
acquisition of positive charges. The DHDMI/DSPC/DPPE-PEG converted to cationic liposomes
at pH 6.0 and had less binging with the positively charged UA stain, thus appearing to be
brighter compared with pH 7.4. The two differently stained phases on DHDMI/DSPC/DPPEPEG indicated different extent of binding with UA. In response to acidic pH, the clustering of
protonated DHDMI and negatively charged DPPE-PEG would cause phase separation on the
liposomes. The phase without clustered DPPE-PEG would display excess positive charges than
the phase with clustered DPPE-PEG, thus being stained less by UA than the phase with clustered
DPPE-PEG. The sharper and clearer boundary of the two phases on DHDMI/DSPC/DPPE-PEG
in Figure 4.5 (d) indicated the phase separation of liposomes was enhanced by the acidic pH 6.0.
Based on the TEM images of cholesterol ICL, the DHI/PSPC/DPPE-PEG,
DHMI/PSPC/DPPE-PEG and DHDMI/PSPC/DPPE-PEG liposomes appeared to be
homogeneous vesicles with size of 80-150 nm. The sizes of ICL obtained by DLS (2.3.2) (100200 nm) were generally larger than the sizes observed under TEM, which is probably because
the thickness of the hydrated PEG coating was also counted into the size measurement of ICL by
DLS. It has been known that the monomer length of PEG (2 kDa) is 0.35 nm [217]. But due to
the hydrophilicity of PEG, they are known to bind with water molecules to form a hydration
shell that surrounds the liposome [51]. Such hydrated PEG coating was reported to have
thickness of 10 nm [218], which can probably explain the gap between the sizes of ICL measured
by DLS and observed under TEM.
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As can be seen in Figure 4.6 (a-c), the morphology of DHI/DSPC/DPPE-PEG/Chol is not
as spherical and homogenized as the cholesterol-free ICLs (such as DHI/DSPC/DPPE-PEG in
Figure 4.3). The liposomes containing cholesterol Figure 4.6 (a-c) showed 80-200 nm size, and
some layered structures can be seen inside of the liposomes. Figure 4.6 (d-f) showed that the
liposomes containing cholesterol had some morphological change in response to acidic pH, but it
didn’t show the pH-triggered brighten particles and phase separation seen in images of
cholesterol-free liposomes.

a.

b.

c.

d.

e.

f.

pH 7.4

pH 6.0

Figure 4.6. TEM images of DOX-loaded DHI/DSPC/DPPE-PEG/Chol at pH 7.4 (a-c) and 6.0 (df).
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4.3.2 Morphology of ICL interacting with model liposomes. Compared with
morphology of DHMI/DSPC/DPPE-PEG liposomes (Figure 4.7 (a)), the large membrane
structures (150-300 nm) surrounded by the small liposomes in Figure 4.7 (b-c), are considered
model liposomes, while the small liposomes are DHMI liposomes. At pH 6.0 (Figure 4.7 (d-f)),
DHMI/DSPC/DPPE-PG liposomes appeared to assemble on the model liposomes, forming
aggregation at the size of 300-600 nm. This result implied at acidic pH, the
DHMI/DSPC/DPPE-PEG liposomes became positively charged to interaction with negatively
charged model liposomes.

a.

b.

c.

d.

e.

f.

pH 7.4

pH 6.0

Figure 4.7. TEM images of DOX-loaded DHMI/DSPC/DPPE-PEG at pH 7.4 (a) and DOX-loaded
DHDMI/DSPC/DPPE-PEG mixed with mode liposomes at pH 7.4 (b-c) and 6.0 (d-f).
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4.4 Summary
The morphology of ICL formulations at physiological pH 7.4 and acidic pH 6.0 were
characterized by TEM in this chapter’s studies. Signified by TEM images of liposomes at pH
7.4, cholesterol-free ICL possess spherical and homogeneous morphology, while the addition of
cholesterol made ICL more heterogeneous in shape (Figure 4.6 (a-c)). The morphological
changes of cholesterol-free ICL in response to acidic pH suggested the acquisition of positive
charges and phase separation, which was consistent with the results of elevated ζ- potentials in
Chapter III (Figure 3.3) and our previous DSC thermogram report (Figure 3.2). The pHtriggered response of ICL containing DHI, DHMI and DHDMI was also in line with their pKa
(DHI < DHMI < DHDMI) (Table 3.1). The DHDMI liposomes appeared to show the most
evident phase separation at acidic pH but also some phase separation at pH 7.4. The DHMI
liposomes showed considerable morphological response to acidic pH. The DHI liposomes
showed a little change from pH 7.4 to 6.0. The bursting of ICL containing DHMI in response to
acidic pH revealed in TEM images was consistent with their pH-triggered drug release (Figure
3.5 and 3.6). At acidic pH, the ICL with cholesterol did not show the interaction between the
lipid components. The aggregation of ICL with negatively charged model liposomes at pH 6.0
was imaged by TEM, which further testified the positive electrification of ICL in response to
acidic pH, which supported the results in Chapter III (Figure 3.4). Overall, the morphological
studies by TEM significantly supported the proposed pH-sensitivity of ICL.
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CHAPTER 5: EVALUATION OF ANTICANCER ACTIVITY OF DOX-LOADED IMIDAZOLEBASED CONVERTIBLE LIPOSOMES ON 3D MULTI-CELLULAR SPHEROIDS (MCS)
5.1 Introduction
2D monolayer cell culture has been widely utilized as in vitro bio-models to test the
activity of anticancer drugs, but they are not able to mimic the acidic microenvironment of solid
tumors in vivo. In previous studies in our group, to evaluate the pH-triggered anticancer activity
of DOX-ICL in 2D monolayer cell culture, the cells were incubated with the ICL liposomes that
were diluted in growth media whose pH was adjusted to 6.0, 6.5, 7.0 and 7.4. The pH-sensitive
ICL formulations showed increasing cytotoxicity on both HeLa and B16F10 cells as the growth
media pH was lowered from 7.4 to 6.0 at DOX concentration of 10 μg/mL (Figure 5.1). By
contrast, the cytotoxicity of NSL (DSPC/DPPE-PEG) at pH 6.0 showed no significant difference
from pH 7.4, suggesting that pH-sensitivity of ICL substantially contributed to their anticancer
activity. Among the three ICL formulations, the DHDMI liposomes, which interacted the most
with model liposomes at pH 6.0, showed the most activity, suggesting that more interaction with
cancer cells by ICL can enhance their cytotoxicity (Figure 3.4 (a)).

(a) Cell Viability on 2D B16F10
Cells
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(Figure 5.1 Continued)
(b) Cell Viability on 2D HeLa Cells

Figure 5.1. Cytotoxicity of free DOX, DOX-loaded liposome and empty liposome against B16F10 cells (a) and HeLa cells (b) after 12 hours of incubation. Data presented as mean ± SD, N = 4.
[129]
As introduced in Chapter I 1.5, 3D multicellular spheroids (MCS) are more representative
in vitro models of solid tumors than 2D monolayered cells. Therefore, MCS have been widely
utilized to study tumor biology and to evaluate bioactivities of drugs. Owing to lower oxygen
and nutrient distribution in their core, MCS possess a necrotic core of lower oxygen level, lower
pH, and similar profile of gene expression compared to solid tumors in vivo [22, 146]. In
contrast to 2D monolayer cells in culture, 3D MCS carries complex extracellular matrix (ECM)
composed of structural proteins of great importance to cell survival, proliferation, and migration
in solid tumors [150, 219]. In previous studies on ICL, the growth media of the 2D monolayer
cells were extrinsically adjusted to carry low pH. By contrast, the acidic microenvironment in
the core of 3D MCS is intrinsically generated, and thus is expected to trigger our pH-sensitive
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ICL formulations as the acidic core of solid tumors would in vivo In contrast to 2D monolayer
cells, the 3D MCS also impose an additional barrier for drug penetration through multiple layers
of cancer cells as solid tumors in vivo.
The studies reported in this chapter aimed to establish 3D MCS of several commonly
used cancer cells lines and to use them to evaluate the anticancer activity of ICL in comparison
with NSL and free DOX. The 3D MCS of HeLa, A549, MDA-MB-231 and MDA-MB-468 cells
were constructed and characterized to discover suitable conditions for the following anticancer
studies. Both the cholesterol-free formulations (with pH-sensitivity) and the formulations with
cholesterol (with better physicochemical characteristics) were tested on the MCS models in order
to compare the impact of pH-sensitivity and physicochemical characteristics (size and EE) on the
anticancer activity.
5.1.1 Necrotic cores of 3D MCS. Similar to the avascular regions of solid tumors, cells
in MCS form three distinct layers, namely the outer layer composed of proliferating cells, the
middle layer composed of quiescent cells, and the inner core of necrotic cells [22].
The formation of the three-layer structure is correlated to the insufficient oxygen
penetration and depends closely on spheroid volume. It was reported that MCS of 500 µm or
larger in diameter would assume the three-layer cell organization, which represents the cell
heterogeneity in solid tumors [143, 144]. The live/dead fluorescence assay is commonly used to
assess the viability of cells and distribution of the necrotic core in MCS assisted with confocal
imaging [144]. The necrotic regions in HeLa, A549, MDA-MB-231 and MDA-MB-468 MCS
were previously imaged using the live/dead fluorescence assay by our group (Figure 5.2) [13].

119

a.

b.

c.

d.

Figure 5.2. Confocal images of the distribution of live and dead cells in HeLa (a), A549 (b), MDAMB-231 (c) and MDA-MB-468 (d) 3D MCS. Live cells display green fluoresce while dead cells
red. [220, 221]
5.1.2 pH gradient of 3D MCS. In contrast to normal cells, cancer cells have higher
intracellular pH (pHi) and acidic extracellular pH (pHe) [12]. This reversed pH gradient
contributes to the accelerated growth rate, invasion and migration of cancer cells [13]. Because
3D MCS possess a hypoxic extracellular environment that is similar to solid tumor, 3D MCS
also has a gradient of extracellular pH decreasing from the periphery to the core. Many confocal
imaging studies have confirmed such a pH gradient inside MCS using pH-dependent fluorescent
probes. The measured pH value inside MCS, although verified to be acidic, varies depending on
cell lines, size, growth rate and culturing conditions. The pH in outer layer of glioma cell MCS
was found to be 7.43, while the pH in the central necrotic core was 6.86, based on the ratio of
SNARF-1 fluorescence at different wavelengths [222]. In a study that measured the pH at the
surface of cells in MCS and in animal tumor models of HeLa, M4A4 and NM2C5 cells, the pH
in the center of MCS was 6.7-6.8, while the pH in the in vivo tumor core was 6.1-6.4 [223]. Our
previous studies [220, 221] also found the pH gradient in MDA-MB-468 MCS from 7.71 in
periphery to 6.36 in center, based on the fluorescent confocal images of spheroids treated with
SNARF-1. Due to the gap between the intrinsic acidity in MCS and in vivo tumors, pHe of some
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MCS models were further acidified by buffered media at similar pH with pHe in solid tumor
cores [224-226]. Reduced drug cellular uptake was found in this type of acidified MCS, which
indicated the lowered pHe (pH 6.0-6.4) in solid tumors was responsible to their limited drug
uptake.
In this chapter’s studies, the intrinsic acidic pHe in MCS is expected to trigger ICL
formulations when they penetrate to the interstitium of MCS.
5.2 Materials and Methods
5.2.1 Materials. The HeLa, A549, MDA-MB-231 and MDA-MB-468 cell lines were
purchased from ATCC (Manassas, VA, US). The Dulbecco’s Modification of Eagle’s Medium
(DMEM) media, Advanced DMEM/F12 media, Trypsin-EDTA, L-Glutamine, fetal bovine serum
and collagen was purchased from Thermo-Fisher Scientific (Waltham, MA, US). The RPMI
1640 media, Penicillin-Streptomycin, 96-well Ultra-low Attachment Round-button microplates,
96-well Solid White microplates and CellTiter-Glo 3D cell viability assay were purchased from
VWR (Radnor, PA, US).
5.2.2 Constructions of 3D MCS Models
5.2.2.1 Cell culture maintenance. Cervical cancer cell line HeLa, lung cancer cell line
A549, and breast cancer cell lines MDA-MB-231 and MDA-MB-468 were cultured to construct
MCS for the evaluation of anticancer activity. HeLa cells were maintained in DMEM media
(with L-glutamine supplement) (Gibco, Carlsbad, CA, US). A549 cells were maintained in
RPMI 1640 media (with L-glutamine supplement) (Corning, NY, US). The DMEM and RPMI
1640 media were supplemented with 10% fetal bovine serum (Gemimi, West Sacramento, CA)
and 1% Penicillin-Streptomycin (Corning, NY, US). MDA-MB-231 and MDA-MB-468 cells
were maintained in Advanced DMEM/F12 reduced serum media (Gibco, Carlsbad, CA, US)
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supplemented with 5% fetal bovine serum, 1% Penicillin-Streptomycin and 1% L-glutamine
(Invitro, San Diego, CA). All cells were grown in a humidified atmosphere of 5% CO2 in air at
37°C and passaged at 85% confluence.
5.2.2.2 Seeding and culturing of MCS. HeLa (~2000 cells/well), A549 (~5000
cells/well), MDA-MB-231 (~3000 cells/well) and MDA-MB-468 (~2000 cells/well) cells were
seeded in 96-well Ultra-low Attachment (ULA) round-bottom Microplates (Corning, NY, US) on
complete growth media containing collagen (Thermo-Fisher Scientific, Waltham, MA, US). An
aliquot (100 μL) of cell suspension was added into each well in 96-well plates, and the cell
concentrations were determined with a Handheld Automated Cell Counter (Millipore,
Burlington, MA, US). The cells were centrifuged (Table 5.1) at 7°C to aggregate in the plates.
Complete growth media (100 L) was added into each well on the second day after seeding. The
growth media were partially changed every other day by replacing 100 μL of media in each well
with 100 μL fresh growth media to maintain a 200 μL/well total media volume. All MCS were
grown in a humidified atmosphere of 5% CO2 in air at 37°C.
5.2.2.3 Morphology of MCS. The morphology of 3D MCS was examined on an inverted
microscope (Keyence, Osaka, Japan), and the size of MCS was measured by BZ-X Analyzer.
The spheroid volume was calculated using the following formula,
𝑆𝑝ℎ𝑒𝑟𝑜𝑖𝑑 𝑉𝑜𝑙𝑢𝑚𝑒 =

1
× 𝐿 × 𝑆2
2

Where L = the long axis of spheroid, S = the short axis of spheroid. The MCS reaching 500 μm
in diameter are subjected to drug treatment as a stringent and representative model.
5.2.2.4 Determination of sensitivity of MCS to anticancer drug DOX. Cell viability of
MCS treated by free DOX at incremental concentrations for 72 hours was obtained to determine
the sensitivity of MCS to DOX, and to develop cytotoxicity assays for DOX-loaded liposomes
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against MCS. The MCS were treated by free DOX for 72 hours as in 4.2.2.2 and then assayed as
in 4.2.2.3. IC50 (μM) of DOX against MCS of each cell line was then determined.
5.2.3 Cytotoxicity assays on 3D MCS treated with DOX-loaded formulations
5.2.3.1 Pretreatment of DOX-loaded liposomes. Before administration to MCS, the
DOX-loaded liposomal formulations were pretreated to remove the unencapsulated DOX in the
liposome suspension, which was generated by leakage during sample storage. The DOX-loaded
samples stored at 4°C for over 10 days needed the pretreatment before administration to MCS.
The DOX-loaded liposomes were mixed with the cation-exchange resin Dowex 50WX-4
(pretreated as in 2.2.2.2) at DOX: resin = 1:60 (w/w) and shaken on an orbital shaker (Thermo
Fisher Scientific, Waltham, MA) at approximately 100 rpm for 25 min at room temperature. The
resin was then removed by filtering the mixture though glass wool in a syringe. The
concentration of the payload DOX of pretreated liposomes was then measured as in 2.2.4.
5.2.3.2 Treatment of 3D MCS with DOX-loaded liposomes. One hundred microleter or
more growth media in each well of 96-well ULA microplate containing 200 μL media and MCS
was replaced with same volume of DOX-loaded liposome or free DOX solutions in complete
media at incremental concentrations. The complete media solutions of DOX were prepared by
diluting water solutions of DOX with complete growth media by 6-10 folds. The final DOX
concentration in each well was calculated according to the fold of dilutions. The incremental
concentration set was determined referring to IC50 obtained in 4.2.2.4. Each treatment by DOXloaded liposomes orfree DOX solutions were quadruplicated. The MCS were incubated in a
humidified atmosphere of 5% CO2 in air at 37°C for 72 hours.
5.2.3.3 Cell viability of 3D MCS after treatment by DOX-loaded liposomes. After 72hour incubation, each MCS was transferred into a 96-well Solid White microplate (Corning, NY,
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US) together with 100 μL media from each well and mixed with 100 μL reagent of CellTiter-Glo
3D cell viability assay (Promega, WI, US) was added to each well. The microplate was covered
with foil and shaken on an orbital shaker for 5 min, then incubated for 25 min at room
temperature. The luminescence of the above mixture was measured on the Synergy HT
microplate reader (Biotek, Winooski, VT, US). The luminescence of MCS treated by growth
media with no drug/formulation were referred as 100% cell viability.
5.3 Results and Discussion
5.3.1 Conditions to construct MCS models. The effect of collagen and cell seeding
number on the morphology of MCS was studied to explore the most suitable set of conditions to
construct MCS models with different cancer cell lines.
5.3.1.1 The effect of collagen. Aiming to construct MCS with spherical structures and
clear edges, collagen was mixed with cells to be seeded in ULA 96-well plates. A comparison of
morphology of MDA-MB-468, A549 and HeLa MCS seeded with and without collagen are
shown in Figure 5.3. The MDA-MB-468 seeded with 1% collagen, A549 seeded with 0.3%
collagen and HeLa seeded with 0.1% collagen formed spherical solid structures. The MDA-MB468 cells seeded without collagen appeared to be loose and scattered cells (Figure 5.3 (a)). The
A549 cells seeded without collagen formed an irregular non-spherical aggregation (Figure 5.3
(b)), which appears denser than MDA-MB-468 without collagen. The HeLa cells seeded without
collagen (Figure 5.3 (c)) formed a solid and spherical structure, but with a rougher edge than the
HeLa cells seeded with collagen.
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a.

b.

c.

No
Collagen

With
Collagen

Figure 5.3. (a) Morphology of MDA-MB-468 MCS seeded with no collagen (upper, 2000
cells/well, 9 days) and 1% collagen (lower, 2000 cells/well, 9 days). (b) Morphology of A549 MCS
seeded with no collagen (upper, 5000 cells/well, 9 days) and 0.3% collagen (lower, 5000 cells/well,
4 days). (c) Morphology of HeLa MCS seeded with no collagen (upper, 500 cells/well, 10 days)
and 0.1% collagen (lower, 2000 cells/well, 7 days).
As a component of the extracellular matrix (ECM), collagen is the most prevalently
utilized embedding material to aggregate cells for the growth of 3D spheroids [224]. The
concentration of collagen needed for MCS formation changed over different cell lines, probably
because it served to only complement various levels of the ECM substrates that were generated
by cancer cells in culture. Our results show that, without collagen, different types of cancer cells
could grow into three different types of morphologies – loose cells, irregular aggregated cells,
and spheroids. HeLa cells formed spheroids without collagen and spheroids with very smooth
edges with only 0.1% collagen. Similarly, the results suggested that A549 probably generate
more substrates than MDA-MB-468. In comparison, A549 needed the addition of 0.3% collagen
to form spheroids, while MDA-MB-468 needed 1%.
5.3.1.2 Cell seeding density. A number of different cell seeding densities were tested to
find its effect on the construction of MCS. As shown in Figure 5.4, with incremental seeding
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densities, the MDA-MB-468 MCS had increasing diameters. The MCS seeded at 5000 and
10000 cells/well started to have rough edges after cultured for 7-9 days, and subsequently
became more scattered over time. The MCS seeded at 2000 cells/well also showed rough edges
but after a longer period of 15 days. This result indicated as the seeding density getting higher or
spheroids growing larger, they start to lose the tight, smooth edge. The MDA-MB-468 MCS
seeded at 2000 cells/well still had a clear edge after reaching a diameter of 500 μm, which can be
the most suitable seeding and growing condition for MDA-MB-468 MCS. The scattering of cells
is also probably due to increase of aggressiveness of cancer cells after being cultured for over
time due to the hypoxia of the newly formed solid core (darker area in Figure 5.4) in the
spheroids.

Day 5

Day 7

Day 9

Day 11

Day 13

Day 15

1000
cells/well

2000
cells/well

5000
cells/well

10000
cells/well

Figure 5.4. Morphology of MDA-MB-468 MCS (500, 1000, 2000, 5000, 10000 cells/well)
seeded with 1% collagen after 5, 7, 9, 11, 13, 15 days in the ULA 96-well microplates.
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As shown in Figure 5.5, for the HeLa cell line, which is likely to generate more ECM
substrates during the growth of spheroids (Figure 5.3), the increases of seeding density did not
induce scattering of cells, but induced more irregular edge of spheroids. Such deformation in
response to higher seeding density was considered as a critical factor to determine the suitable
seeding density of the construction of HeLa MCS.

1000
cells/well

2000
cells/well

5000
cells/well

Figure 5.5. Morphology of HeLa MCS (1000, 2000, 5000 cells/well) seeded with 0.1% collagen
after 6 days in the ULA 96-well microplates.
Similarly, the suitable conditions to construct MCS ofother cancer cells were selected
based on the morphology of spheroids. The conditions to construct HeLa, A549, MDA-MB-231
and MDA-MB-468 3D MCS are summarized in Table 5.1. Both the collagen free (500
cells/well) and 0.1% collagen (2000 cells/well) conditions suitable to form HeLa MCS. The
collagen-free HeLa MCS was later used in our cytotoxicity studies. Typical morphology of the
~500 μm HeLa, A549, MDA-MB-231 and MDA-MB-468 MCS for anticancer drug treatments
are shown in Figure 5.6.

Table 5.1
Conditions to construct 3D MCS models with HeLa, A549, MDA-MB-231 and MDA-MB-468
cancer cells.
Cell Line

Hela

A549

MDA-MB-231

MDA-MB-468
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(Table 5.1 Continued)
Seeding Density (cells/well)

500

2000

5000

3000

2000

Collagen (%)

0

0.1

0.3

1

1

300

200

200

Centrifuge Speed (g)

1000 1000

Centrifuge Time (min)

15

15

7

15

15

Estimated time to reach
500 μm diameter (days)

12

6

5

5

11

a.

b.

c.

d.

Figure 5.6. Representative morphology of MCS for anticancer drug treatment: HeLa MCS (500
cells/well, no collagen, 12 days) (a), A549 MCS (5000 cells/well, 0.3% collagen, 5 days) (b),
MDA-MB-231 MCS (3000 cells/well, 1% collagen, 5 days) (c) and MDA-MB-468 MCS (2000
cells/well, 1% collagen, 11 days) (d) with diameter of 500 μm in the ULA 96-well microplates.
5.3.1 Inhibition on growth of MCS by DOX. The constructed 3D MCS models were
treated with DOX at incremental concentrations to record morphology and cell viability. As can
be seen in Figure 5.7, the HeLa MCS exposed to incremental DOX concentration for 72 hours
showed significant changes in morphology. As the DOX concentration increased from 0 to 2
μM, the spheroid became smaller, which signified that DOX inhibited the growth of spheroids.
As the DOX concentration increased from 2 to 100 μM, the spheroid showed more and more
rough edges and became looser, which indicated the deformation of of the spheroids. As the
DOX concentration increased from 100 to 500 μM, the spheroids showed smaller sizes besides
more rough edges, which indicated remarkable loss of cells accompanying the deformation of
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MCS by DOX.

a.
Before
treatme
nt

b.

72 hours
after
treatmen
t

0 μM

0.2 μM

0.5 μM

1 μM

2 μM

5 μM

10 μM

20 μM

50 μM

100 μM

200 μM

500 μM

Figure 5.7. Morphology of HeLa MCS before (a) and after (b) treatment by DOX (72 hours
exposure) at incremental concentrations.
The half maximal inhibitory concentration (IC50) values of free DOX on HeLa, A549,
MDA-MB-231 and MDA-MB-468 MCS (Table 5.2) were calculated from cell viability results in
Figure 5.8 using the GraphPad Prism software. The IC50 values reported the sensitivity of each
3D MCS model to DOX, which helped determinate the suitable DOX concentration set for the
cytotoxicity assay of DOX-loaded ICL. Treatment by free DOX on MCS was also carried out
for comparison in the cytotoxicity assay of liposomes.
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Figure 5.8. Cell viability of HeLa, A549, MDA-MB-231 and MDA-MB-468 MCS treated with
free DOX for 72 hrs. Data presented as mean ± SD, N = 4.
Table 5.2
IC50 of free DOX on HeLa, A549, MDA-MB-231 and MDA-MB-468 3D MCS.
Cell Line

Hela

A549

MDA-MB-231

MDA-MB-468

IC50 (μM)

1.26±0.04

12.59±1.05

1.18±0.29

0.32±0.12

Note. Data presented as mean ± SD, N = 4.
5.3.2 Cytotoxicity of ICL on 3D MCS. After treatment by cholesterol-free ICL, NSL
and free DOX for 72 hours, the cell viability of 3D MCS was recorded. As shown in Figure 5.9
(a), the DHI and DHMI liposomes showed better anticancer activity than NSL against HeLa
MCS, while DHDMI showed similar activity to NSL. In Figure 5.9 (d), the DHI, DHMI and
DHDMI liposomes showed better anticancer activity than NSL on MDA-MB-468 MCS, but the
improvement is not as evident as on HeLa MCS. On both HeLa and MDA-MB-468 MCS, the
DHMI liposomes expressed the best anticancer activity and was comparable to free DOX. As
can be seen in Figure 5.9 (b), compared with NSL, ICL did not show better activity on A549
MCS except for DHI at the highest DOX concentration of 100 μM. In Figure 5.9 (c), ICL
showed similar inhibition trend with NSL.
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Figure 5.9. Cell viability of Hela (a), A549 (b), MDA-MB-231 (c), MDA-MB-468 (d) MCS
treated with cholesterol-free ICL, NSL and free DOX for 72 hours. Data presented as mean ± SD,
N = 4.
Figure 5.10 showed the results of cytotoxicity of free DOX, ICL and NSL containing
25% cholesterol on 3D MCS. All the ICL formulations showed similar anticancer activity with
NSL against HeLa, A549 and MDA-MB-231 MCS.
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(Figure 5.10 Continued)

Figure 5.10. Cell viability of Hela, A549, MDA-MB-231 MCS treated with cholesterol-containing
ICL (25 mol%), cholesterol-containing NSL (25 mol%) and free DOX for 72 hours. Data presented
as mean ± SD, N = 4.
According to the pH-sensitivity studies (Chapter III), the cholesterol free ICL showed
pH-sensitivity in terms of displaying positive surface charges and drug release, while the ICL
containing cholesterol did not show pH-sensitivity. Our cytotoxicity studies were carried out on
MCS models, which were confirmed to provide an acidic extracellular microenvironment. The
MCS cytotoxicity studies showed that ICL containing cholesterol exerted similar anticancer
activity with NSL, in contrast to the cholesterol-free ICL, which showed evidently higher
anticancer activity than NSL on two MCS models. The cytotoxicity results were consistent with
the pH-sensitivity, which suggested that the cholesterol-containing ICL lost their anticancer
activities because the addition of cholesterol suppressed the liposomal pH-sensitivity from the
imidazole-based lipids. On the HeLa and MDA-MB-468 MCS, the cholesterol-free ICL with
DHMI showed the most anticancer activity among the formulations and was comparable with
free DOX. The other cholesterol-free ICL containing DHI and DHDMI, even though showed
upgraded activity compared with NSL, they expressed lower activity compared with free DOX.
The lower activity of ICL compared with free DOX is probably due to the limited penetration of
liposomes compared with small molecule drugs. Based on the cell viability results in Figure 5.9
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and 5.10, the IC50 values of cholesterol-free ICL, ICL containing cholesterol and free DOX on
MCS were calculated and are summarized in Table 5.3, which shows noticeable increase of IC50
of ICL with cholesterol compared with the cholesterol-free ICL.

Table 5.3
IC50 values of DOX-loaded liposomes and free DOX on HeLa, A549, MDA-MB-231 and MDAMB-468 3D MCS.
Lipid Mol
MDAMDAIC50 (μM)
Hela
A549
Ratio
MB-231
MB-468
DHI/DSPC/DPPE25/70/5
3.82±1.13***
~30
1.38±1.31 0.38±0.21**
PEG
DHMI/DSPC/DPPE
25/70/5
2.07±1.13***
~40
1.77±1.21 0.31±0.15***
-PEG
DHDMI/DSPC/DPP
25/70/5
9.51±1.15
~35
1.86±1.24 0.63±0.10**
E-PEG
DSPC/DPPE-PEG
DHI/DSPC/DPPEPEG/Chol
DHMI/DSPC/DPPE
-PEG/Chol
DHDMI/DSPC/DPP
E-PEG/Chol
DSPC/DPPEPEG/Chol
Free DOX

95/5

11.41±1.28

~35

2.37±1.29

1.24±0.13

25/45/5/25

~10

~30

5.13±1.46

-

25/45/5/25

10.38±1.33

29.07±2.73

3.62±1.17

-

25/45/5/25

~10

24.06±1.40

3.26±1.18

-

70/5/25

~10

33.88±1.62

3.98±1.10

-

-

1.26±0.04

12.59±1.05

1.18±0.29

0.32±0.12

Note. Data presented as mean ± SD, N = 4. ** p < 0.01, *** p < 0.001 (to the IC50 of
DSPC/DPPE-PEG)
Among these three ICL that do not contain cholesterol, the ranking of anticancer activity
against 3D MCS was DHMI > DHI > DHDMI. According to the pH-sensitivity studies, the
ranking of acidic pH-triggered cationic conversion is DHDMI > DHMI > DHI, while the ranking
of acidic pH-triggered drug release is DHMI > DHI > DHDMI. Ranking of their activity on 2D
monolayered cells, as reported in our previous cytotoxicity studies (Figure 5.1), was precisely in
line with their pH-triggered cationic conversion. However, their activity on 3D MCS appeared
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to be more consistent with their pH-triggered drug release. In 2D cell culture at acidic pH, the
ICL would convert to cationic liposomes and have better interaction with cancer cells, thus
significantly improved the local concentration of drug on cells. In 3D MCS models, ICL would
be triggered by acidic pH after penetrating into the acidic interstitium of MCS, where the
enhanced local concentration of drug induced by improved liposome-cell interaction might take
less effect. In the meantime, the cellular uptake of DOX inside MCS would be more affected by
the drug release at the acidic interstitial space inside MCS.
5.4 Summary
3D MCS models of HeLa, A549, MDA-MB-231 and MDA-MB-468 cell lines were
successfully constructed under optimized conditions. The anticancer activity of DOX-loaded
ICL in comparison with DOX-loaded NSL and free DOX was evaluated with cytotoxicity on
MCS models. Based on the IC50 values, the cholesterol-free ICL, especially the DHMI
liposomes, showed upgraded anticancer activity against MCS compared with NSL. The addition
of cholesterol resulted in lower activity of ICL and caused ICL to show similar inhibition trend
with NSL, which was consistent with the previously reported suppression of ICL pH-sensitivity
by the addition of cholesterol (Chapter III). The cholesterol-free ICL were studied in comparison
with ICL containing cholesterol because the pH-sensitivity of cholesterol-free ICL and the better
physicochemical characteristics (size and EE) of ICL containing cholesterol were both expected
to improve the anticancer activity of liposomes on MCS. Our cytotoxicity studies indicated that
the anticancer activity of the ICL is mostly enhanced by their pH-sensitivity.
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CHAPTER 6: SUMMARY
As the second leading cause of death globally, cancer is a major concern for human
health. Most cancers form malignant solid tumors, which possess different biological features
from healthy tissues, including fenestrated vascular walls, hypoxia, necrosis, acidic
microenvironment, and unique extracellular matrix (ECM). These abnormal features pose
challenges as well as opportunities for anticancer treatment. Poorly developed vasculature in
tumor compared to normal vasculature present unique advantages for nanomedicines over small
molecule drugs against cancer. Nanomedicines more easily move from the porous tumor blood
vessel into tumor interstitium and then accumulate there due to the lack of tumoral lymphatic
drainage, a phenomenon known as the enhanced permeability and retention (EPR) effect.
Moreover, the acidic pH in tumor interstitium (pH 6.0-7.0) represents a promising stimulus to
trigger nanomedicines to promote cellular uptake of the cargo drugs.
Liposomes are capable nanocarriers of both hydrophilic and hydrophobic agents due to
the amphiphilicity of their lipid components. Liposomes are the most commonly used
nanocarriers and have yielded multiple nanomedicine products in the market by now. The
previously reported stealth liposomes coated with PEG have shown enhanced accumulation in
tumors owing to their prolonged circulation time. However, the PEG coating also hinders their
interaction with cancer cells. In order to improve the anticancer activity of stealth liposomes by
improving their interaction with cancer cells, but without removing their long circulation
(stealth) property, three novel, synthetic imidazole-based lipids were introduced to the liposome
composition to develop the pH-sensitive, imidazole-based convertible liposomes (ICL). At
acidic pH, the imidazole-based lipids would protonate to acquire positive charges, thus clustering
with the negatively charged PEGylated lipids. Such lipid-lipid electrostatic interaction would
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induce phase separation of the bilayer to generate a PEG-free domain, which displays excess
positive charges and have enhanced interaction with negatively charged cancer cells. The pHsensitivity introduced by the imidazole-based lipids is expected to improve the anticancer
activity of stealth liposomes.
The ICL formulations were successfully prepared, characterized, and optimized to have
small particle sizes (< 200 nm) and sufficient EE (> 40%). After synthesizing the imidazolebased lipids DHI, DHMI and DHDMI, ICL were prepared using film hydration, freeze-annealthawing, and extrusion methods. Doxorubicin (DOX) was chosen as the cargo drug to be loaded
in ICL using the remote loading method with manganese sulfate gradient. A collection of
methods was used to improve the physicochemical characteristics of ICL, including reducing
loading time, incorporating cholesterol, mixing with resin at T ≥ Tm, filtration, and reducing the
input DOX concentration. Incorporating cholesterol and reducing the input DOX were found to
be the most feasible methods to improve the physicochemical properties of ICL by maintaining
both small size and high EE.
The ICL formulations were tested on their pH-sensitivity. ζ- potential change, interaction
with model liposomes, and drug release of ICL in response to the change of pH (6.0-7.0) were
assayed to test the pH-sensitivity of ICL with and without cholesterol. In response to the drop of
pH, the cholesterol-free ICL raised their ζ- potentials and aggregated with negatively charged
model liposomes. The drop of pH also enhanced the drug release from cholesterol-free ICL.
Among the three ICL formulations, the DHDMI/DSPC/DPPE-PEG showed the most substantial
pH-triggered conversion to cationic liposomes, while the DHMI/DSPC/DPPE-PEG showed the
most significant pH-triggered drug release. However, ICL with cholesterol didn’t show any of
such changes at lowered pH.
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Transmission electron microscopy (TEM) was used to study the morphology of ICL and
their interaction with model liposomes at physiological pH 7.4 and acidic pH 6.0. At pH 7.4, the
cholesterol-free ICL samples showed intact, spherical, and homogeneous vesicles, while the ICL
with cholesterol showed more heterogeneous in shape. At pH 6.0, the surface of cholesterol-free
ICL, especially DHDMI/DSPC/DPPE-PEG, showed evident phase separation. In contrast, the
ICL with cholesterol did not show phase separation. TEM also showed that the cholesterol-free
ICL aggregated with negatively charged model liposomes at pH 6.0 but had no interactions with
model liposomes at pH 7.4, which demonstrated their pH-triggered conversion into cationic
liposomes.
The anticancer activities of ICL formulations were evaluated in MCS in comparison with
non-sensitive stealth liposomes (NSL). 3D multicellular spheroids (MCS) were chosen to assess
the anticancer activities of liposomes, because they more closely resemble the biological features
of solid tumors than 2D cell cultures, including the acidic microenvironment. The 3D MCS of
HeLa, A549, MDA-MB-231 and MDA-MB-468 cell lines were successfully constructed by
exploring the suitable seeding and culturing conditions. Cytotoxicity assays on 3D MCS were
carried out to evaluate the anticancer activity of ICL formulations. According to the IC50 values,
the cholesterol-free ICL, especially DHMI/DSPC/DPPE-PEG, showed considerably enhanced
activity on MCS compared to NSL. However, ICL with cholesterol showed anticancer activities
that were similar to NSL but lower than cholesterol-free ICL.
In summary, it was found that pH-sensitivity is successfully introduced to PEGylated,
stealth liposomes by the incorporation of imidazole-based lipids, and the pH-sensitivity
correlated with the enhanced anticancer activity of the resultant ICL liposomes. In the pHsensitivity studies, cholesterol-free ICL showed both pH-triggered conversion into cationic
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liposomes and pH-triggered drug release. Under TEM, the phase separation and bursting of ICL
appeared to be consistent with their pH-sensitivity. The IC50 values of ICL formulations against
3D MCS confirmed that liposomes with the pH-sensitivity from the imidazole-based lipids
showed improved anticancer activity than the non-sensitive stealth liposomes. Among the three
ICL formulations, DHDMI/DSPC/DPPE-PEG showed the most pH-sensitivity in conversion,
and the best activity against 2D cancer cells (previous studies); DHMI/DSPC/DPPE-PEG
showed the most pH-sensitivity in drug release as well as the best activity against 3D MCS. It
appears that in 3D MCS, which are more like solid tumors in vivo than 2D cells, the triggered
release of liposomal delivery systems probably plays a more critical role than the enhanced
interaction with cancer cells. Moreover, although the incorporation of cholesterol can improve
the physicochemical characteristics of ICL, it would also suppress the pH-sensitivity of ICL.
Against 3D MCS, unlike the cholesterol-free ICL, the ICL with cholesterol showed similar
anticancer activity with the non-sensitive stealth liposomes, indicating that removing the pHsensitivity of liposomes would decrease the anticancer activity. The pH-sensitivity of ICL played
a more critical role for activities against MCS than good physicochemical characteristics. In
conclusion, the pH-sensitivity introduced by the imidazole-based lipids can enhance the anticancer activity of stealth liposomes.
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